Pyridopyrimidine derivative as small GTP enzyme KRAS mutation inhibitor
By designing pyridopyrimidine compounds with specific structures, the problem of difficult inhibition of the interaction between KRAS G12D mutant and its effector protein in the prior art is solved, and effective treatment of KRAS mutation-related diseases is achieved, especially lung cancer, pancreatic cancer, etc. Potential treatment options for tumors.
Patent Information
- Application Number
- CN202410691054.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-30
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-03
AI Technical Summary
It is difficult to develop effective orally safe small GTPase inhibitors, especially against KRAS G12D mutants, and there are difficulties in inhibiting the interaction of KRAS mutant proteins with their effector proteins, resulting in limited efficacy in treating tumors.
A class of pyridopyrimidine compounds with specific structures is designed to inhibit the interaction of KRAS-effector proteins at very low concentrations for the treatment of diseases associated with KRAS mutations, such as tumors.
This compound significantly inhibits the interaction of KRAS-effector proteins at very low concentrations, providing an effective treatment method for KRAS mutant-related diseases, especially for tumors such as lung cancer, pancreatic cancer, and cholangiocarcinoma.
Smart Images

Figure SMS_1 
Figure SMS_4 
Figure SMS_5
Abstract
Description
Technical Field
[0001] The present application relates to a class of pyridopyrimidine derivatives, a preparation method thereof, a pharmaceutical composition or prodrug or a salt thereof containing these compounds, and a medical use thereof as a small GTPase KRAS mutation inhibitor in the treatment of different tumors. Background Art
[0002] As a human oncogene, RAS is one of the most commonly mutated genes in tumors. RAS mutations are found in about 30% of tumors. If the regulatory factors of RAS and upstream and downstream mutations of the signaling pathway are combined, almost all tumors are covered. The KRAS gene (Kirsten rat sarcoma viral oncogene homolog) is an important member of the RAS gene family. The protein encoded by the KRAS gene is a GDP / GTP binding protein, a small GTPase enzyme, which belongs to the superprotein family. The KRAS protein has 188 amino acids and a molecular weight of 21.6KD. It is located on the inner side of the cell membrane and is connected to the cell membrane through the farnesyl modification gene. KRAS is in an activated state when bound to GTP (KRAS-GTP) and in a closed state (or inactive state) (KRAS-GDP) when bound to GDP. Subsequently, the GTPase activating protein (GAP) can hydrolyze the GTP bound to KRAS-GTP into GDP, prompting the formation of the KRAS-GDP closed state, thereby placing KRAS in an inactive state. The KRAS protein is a "switch" between the KRAS-GTP activated state and the KRAS-GDP inactive state (closed state). In the activated state, it can activate downstream signaling pathways including the MAPK signaling pathway, the PI3K signaling pathway, and the Ral-GDS signaling pathway. The RAS protein switch controls its downstream signaling pathways, thereby promoting cell survival, proliferation, and cytokine release, and plays an important role in life processes such as cell proliferation, differentiation, and apoptosis. KRAS can also be briefly activated by growth factors (such as EGFR). The activated KRAS can activate downstream signaling pathways such as the PI3K-AKT-mTOR signaling pathway that controls cell generation, and the RAS-RAF-MEK-ERK signaling pathway that controls cell proliferation. Mutated KRAS will continue to be activated even in the absence of kinase activation such as EGFR, leading to continued cell proliferation and ultimately cancer.
[0003] KRAS mutations are highly expressed in a variety of tumors, and the most common ones found include lung cancer, intestinal cancer, pancreatic cancer, colon cancer, small intestine cancer, bile duct cancer, etc. Structural studies have shown that most KRAS gene mutations interfere with KRAS's ability to hydrolyze GTP, ultimately causing KRAS to be continuously activated, making it unable to effectively regulate cell signal transduction, thereby promoting the occurrence, development, and metastasis of tumors.
[0004] For KRAS mutations, mutations at amino acid position 12 (G12) account for about 80%, while G12C mutations account for about 14% of all G12 mutations. In recent years, researchers have developed a series of covalent inhibitors for KRAS G12C mutations, but the development of inhibitors for KRASG12D mutations has encountered great challenges.
[0005] At present, no good method has been developed for covalent binding to aspartic acid. The difficulty in directly inhibiting the KRAS G12D mutant is not only that the surface of the protein encoded by KRAS is smooth and lacks binding sites, but also that KRAS binds to GTP / GDP very strongly and the concentration of intracellular GTP / GDP is also very high, which makes it impossible to develop competitive inhibitors for GTP and KRAS. It is also very difficult to develop protein-protein interactions that inhibit or disrupt KRAS mutant proteins and their effector proteins. Not only is the membrane localization of KRAS regulated by farnesyl transferases, etc., but the therapeutic window for targeting KRAS downstream signaling molecules (effector proteins) and inhibiting the wild-type signaling pathway required for growth is narrow. Moreover, due to the compensatory mechanism, it is impossible to completely and effectively inhibit the downstream signals of KRAS mutants, thereby greatly limiting the efficacy of kinase inhibitors developed for effector proteins against KRAS mutations.
[0006] In summary, there is still a great unmet clinical need for the development of small GTPase inhibitors with oral safety and efficacy, such as KRAS G12D mutation inhibitors. Summary of the invention
[0007] The purpose of the present invention is to provide a KRAS mutant inhibitor that is safe and effective for oral administration, in particular, an inhibitor for the treatment of tumors such as colorectal cancer, lung cancer, pancreatic cancer, bile duct cancer, esophageal cancer, breast cancer, and gastric cancer.
[0008] The first aspect of the present invention provides a compound represented by the following formula (I) or formula (II), or a pharmaceutically acceptable salt or a prodrug thereof:
[0009]
[0010] Among them, R 1 Selected from the following group: hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 cyanoalkyl, C1-C6 hydroxyalkyl, allyl, -C(=O)H, -CO2R 5 、-C(=O)R 6 、-SO2R 7 、-CO2N(R 5)2, aryl, heteroaryl, CONH2, CONRaRb or CONHRc; wherein Ra, Rb, Rc are independently selected from: C1-C6 alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl;
[0011] Q is a bond, S, O or NR 5 ;
[0012] R 2 Selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, cyanomethyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkynyl;
[0013] R 3 Selected from the group consisting of H, D, halogen, OH, OR, CH2OH, CH2OR, CN, NH2, NHR, N(R)2, or
[0014] Wherein, R is C1-C4 alkyl, C1-C4 alkoxy;
[0015] And in formula (I), R 3 for
[0016] X is selected from the group consisting of halogen, hydroxyl, mercapto, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkanethio;
[0017] Y is selected from the group consisting of H, halogen, hydroxy, mercapto, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkanethio;
[0018] Z is selected from the group consisting of H, halogen, hydroxyl, mercapto, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkanethio;
[0019] Wherein, the aryl group is C6-C 14 The aryl group and the heterocyclic group are 3-12 membered heterocyclic groups, the heteroaryl group is 5-14 membered heteroaryl group (e.g., 5-6 membered heteroaryl group or benzo 5-6 membered heteroaryl group), and the cycloalkyl group is C3-C 12 and unless otherwise specified, the aryl, heteroaryl and cycloalkyl groups may optionally have 1 to 3 substituents selected from the group consisting of halogen, C1-C6 alkyl.
[0020] R 4 is hydrogen, -N(R 5 )2, heterocyclic group, C1-C6 alkyl group, -M-heterocyclic group, -M-aryl group, -M-heteroaryl group, -M-cycloalkyl group, -MN(R 5 )2, -M-NHC(=NH)NH2, -MC(=O)N(R 5)2, -M-C1-C6 haloalkyl, -M-OR 5 、-M-(CH2OR 5 )(CH2) n OR 5 、-M-NR 5 C(O)-aryl, -M-COOH or -MC(=O)O(C1-C6 alkyl), wherein each heterocyclyl, aryl, cycloalkyl or heteroaryl moiety may be optionally replaced by one or more R 6 wherein the aryl or heteroaryl of -M-aryl and -M-heteroaryl may be optionally substituted by one or more R 7 replace;
[0021] Each M is independently a chemical bond, a C1-C6 alkylene group, or a C2-C6 alkenylene group; wherein the M may be optionally substituted by one or more substituents selected from the group consisting of a hydroxyl group, an amine group, a C1-C4 hydroxyalkyl group, or a heteroaryl group;
[0022] Each R 5 Each is independently hydrogen, C1-C6 alkyl or C1-C6 haloalkyl;
[0023] or R 4 and R 5 and the N atoms connected thereto together form a 4-7 membered saturated nitrogen heterocyclic ring; wherein the 4-7 membered saturated nitrogen heterocyclic ring may be optionally replaced by one or more R 6 replace;
[0024] Each R 6 Each is independently halogen, hydroxy, C1-C6 hydroxyalkyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, cyano, heterocyclic, -L-phenyl, -L-phenylSO2F, -C(=O)NH2, -NHC(=O)phenyl, -NHC(=O)phenylSO2F, heteroaryl, arylC1-C6alkyl-, tert-butyldimethylsiloxyCH2-, -N(R 5 )2, (C1-C6 alkoxy) C1-C6 alkyl-, (C1-C6 alkyl) C(=O), oxo, (C1-C6 haloalkyl) C(=O)-, -SO2F, (C1-C6 alkoxy) C1-C6 alkoxy, -CH2OC(=O)N(R 5 )2, -CH2NHC(=O)OC1-C6alkyl, -CH2NHC(=O)N(R 5 )2, -CH2NHC(=O)C1-C6 alkyl, -CH2(heteroaryl), -CH2heterocyclyl, -CH2NHSO2C1-C6 alkyl, -CH2OC(=O)heterocyclyl, -OC(=O)N(R 5)2, -OC(=O)NH(C1-C6 alkyl)O(C1-C6 alkyl), -OC(=O)NH(C1-C6 alkyl)O(C1-C6 alkyl)phenyl(C1-C6 alkyl)N(CH3)2, -OC(=O)NH(C1-C6 alkyl)O(C1-C6 alkyl)O(C1-C6 alkyl)alkyl)phenyl or -OC(=O)heterocyclyl; wherein the phenyl group of -NHC(=O)phenyl or -OC(=O)NH(C1-C6 alkyl)O(C1-C6 alkyl)phenyl is optionally substituted by -C(=O)H or OH, and the heterocyclyl group in the -CH2heterocyclyl group may also be optionally substituted by oxo;
[0025] Wherein, L is a chemical bond or O;
[0026] Each R 7 Each is independently selected from the following group: halogen, hydroxyl, HC(=O)-, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 hydroxyalkyl or -N(R 5 )2;
[0027] Each R 8 are independently halogen, cyano, hydroxy, C1-C4 alkyl, -S-C1-C6 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C2-C4 hydroxyalkynyl, C1-C6 cyanoalkyl, triazolyl, C1-C6 haloalkyl, -O-C1-C6 haloalkyl, -S-C1-C6 haloalkyl, C1-C6 alkoxy, hydroxyC1-C6 alkyl, -CH2C(=O)N(R 5 )2, -C3-C4 alkynyl (NR 5 )2、-N(R 5 )2, deuterated C2-C4 alkynyl, (C1-C6 alkoxy)halogenated C1-C6 alkyl- or C3-C6 cycloalkyl, wherein the C3-C6 cycloalkyl is optionally substituted by halogen or C1-C6 alkyl;
[0028] R9 is selected from the group consisting of H, halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 deuterated alkyl, C1-C4 haloalkoxy, C2-C4 alkenyl, C3-C6 cycloalkyl;
[0029] R 10 Selected from the group consisting of H, halogen, cyano, hydroxy, nitro, amino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 deuterated alkyl, C1-C4 haloalkoxy, C2-C4 alkenyl, C3-C6 cycloalkyl;
[0030] Each R'1 is independently selected from the group consisting of H, methyl, ethyl, C3-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 cycloalkoxy, C1-C6 cycloalkanethiol, deuterated methyl, deuterated ethyl;
[0031] In another preferred embodiment, the compound has a structure shown in the following formula:
[0032]
[0033] In another preferred embodiment, the compound has a structure shown in the following formula:
[0034]
[0035] Among them, the R 11 is selected from the group consisting of H, deuterium, halogen, methyl, hydroxymethyl, ethyl, C3-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 cycloalkoxy, C1-C6 cycloalkanethiol, deuterated methyl, deuterated ethyl, halomethyl, halomethoxy; or two R 11 The carbon atoms connected thereto together form a 3-9-membered cycloalkyl or heterocyclic group.
[0036] m is 0, 1, 2, 3 or 4.
[0037] In another preferred embodiment, the compound has a structure shown in the following formula:
[0038]
[0039] Among them, the R 11 is selected from the group consisting of H, deuterium, halogen, methyl, ethyl, C3-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 cycloalkoxy, C1-C6 cycloalkanethiol, deuterated methyl, deuterated ethyl, halomethyl, halomethoxy; or two R 11 The carbon atoms connected thereto together form a 3-10 membered cycloalkyl or heterocyclic group.
[0040] m is 0, 1, 2, 3 or 4.
[0041] In another preferred embodiment, the compound has a structure shown in the following formula:
[0042]
[0043] Among them, the R 11 Selected from the following group: H, deuterium, halogen, methyl, ethyl, C3-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 cycloalkoxy, C1-C6 cycloalkanethio, deuterated methyl, deuterated ethyl, halomethyl, halomethoxy.
[0044] m is 0, 1, 2, 3, 4, 5 or 6.
[0045] In another preferred embodiment, R 1 Selected from the group consisting of hydrogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 cyanoalkyl, C1-C6 hydroxyalkyl, HC(=O)-, -CO2R 5 , or -CO2N(R 5 )2.
[0046] In another preferred embodiment, the R 5 Selected from the group consisting of hydrogen, C1-C6 alkyl, or C1-C6 cyanoalkyl.
[0047] In another preferred embodiment, the R 4 having a structure selected from the group consisting of: -M-heterocyclyl, -M-aryl, -M-heteroaryl, -M-cycloalkyl; wherein each heterocyclyl, aryl, cycloalkyl or heteroaryl moiety may be optionally replaced by one or more R 6 wherein the aryl or heteroaryl of -M-aryl and -M-heteroaryl may be optionally substituted by one or more R 7 replace;
[0048] Wherein, the aryl group is C6-C 10 The aryl and heterocyclic groups are 4-6-membered monocyclic heterocyclic groups or 7-9-membered cyclic heterocyclic groups, the heteroaryl groups are 5-6-membered monocyclic heteroaryl groups or 9-10-membered cyclic heterocyclic groups, and the cycloalkyl groups are C3-C6 monocyclic alkyl groups or C7-C 10 Cycloalkyl;
[0049] Each R 6 Each is independently halogen, hydroxyl, C1-C6 hydroxyalkyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, cyano, heterocyclic, C1-C6 alkyl-substituted heteroaryl, aryl C1-C6 alkyl-, -N(R 5 )2, (C1-C6 alkoxy)C1-C6 alkyl-, (C1-C6 alkyl)C(=O), -C(=O)NH2, -CH2(heteroaryl), -CH2heterocyclyl;
[0050] Each R 7 Each is independently selected from the following group: halogen, hydroxyl, HC(=O)-, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 hydroxyalkyl or -N(R 5 )2.
[0051] In another preferred embodiment, the R 4 Having a structure selected from the group consisting of:
[0052]
[0053]
[0054] Preferably, when R 4 When it is the above groups, Q is O, S, NH, CO;
[0055]
[0056] Preferably, when R 4 When it is the above-mentioned group, Q is a single bond.
[0057] In another preferred embodiment, the C1-C6 alkyl group is methyl, ethyl, isopropyl or isobutyl.
[0058] In another preferred embodiment, the Selected from the group consisting of CHF2, CH2F, CF3, CF2Cl, CF2CH3.
[0059] In another preferred embodiment, the compound has the structure shown below:
[0060]
[0061] Among them, in formula IA, IB, IC, (R 1_1 ) n is selected from D, halogen, OH, C1-C4 alkyl, C1-C4 deuterated alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, CH2OH, CH2CH2OH, CH2(C1-C4 alkoxy, CN, NH2); the definitions of the remaining groups are the same as described above.
[0062] In another preferred embodiment, the Having a structure selected from the group consisting of:
[0063]
[0064] In another preferred embodiment, the Having a structure selected from the group consisting of:
[0065]
[0066] In another preferred embodiment, the R 2 Selected from H, D, halogen, C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C3 alkoxy, vinyl, allyl.
[0067] In another preferred embodiment, the R 2Selected from CD3, D, halogen, C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C3 alkoxy, vinyl, allyl.
[0068] In another preferred embodiment, the compound of formula (I) or formula (II) has a structure selected from the following group:
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
[0084]
[0085]
[0086]
[0087] Or the compound of formula (Ia) has a structure selected from the following group:
[0088]
[0089]
[0090] Or the compound of formula (II) has a structure selected from the following group:
[0091]
[0092]
[0093]
[0094]
[0095]
[0096]
[0097]
[0098]
[0099] Or the compound of formula (II-a) has a structure selected from the following group:
[0100]
[0101]
[0102]
[0103]
[0104] The second aspect of the present invention provides the use of the compound according to the first aspect of the present invention for preparing a drug for treating a disease associated with the activity or expression of a KRAS mutant.
[0105] In another preferred embodiment, the disease associated with the activity or expression of the KRAS mutant is a tumor, preferably a tumor selected from the following group: sarcoma, myxoma, rhabdomyomas, fibromas, lipomas, teratomas, bronchial carcinomas, lung cancers, bronchial adenomas, lymphomas, chondroma hamartomas, mesotheliomas, esophageal cancers, gastric cancers, pancreatic cancers, small intestine cancers, large intestine cancers, cecal cancers, genitourinary tract tumors, kidney cancers, bladder cancers, urethral cancers, prostate cancers, testicular cancers, liver cancers, bile duct cancers, hepatoblastomas, angiosarcomas, hepatocellular adenomas, hemangiomas, gallbladder cancers, ampullary cancers, bone cancers, brain cancers, uterine cancers, vaginal cancers, hematological tumors, skin cancers, ovarian cancers, and breast cancers.
[0106] In another preferred embodiment, the KRAS mutant is a KRAS G12D mutant, a KRAS G12V mutant, a KRASG12S mutant or a KRAS G13D mutant.
[0107] The third aspect of the present invention provides a pharmaceutical composition, which comprises: (i) a therapeutically effective amount of a compound of formula I and a compound of formula II as described in the first aspect of the present invention, or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable carrier.
[0108] In another preferred embodiment, the pharmaceutical composition is used to treat diseases related to the activity or expression level of KRAS mutants.
[0109] The fourth aspect of the present invention provides a pharmaceutically acceptable prodrug of the compound according to the first aspect of the present invention, characterized in that the prodrug has a structure as shown in the following formula:
[0110]
[0111] Among them, R 12 Selected from the group consisting of hydrogen, methyl, methoxy, deuterated methyl, ethoxy, ethyl, isopropyl, cyclobutane, oxetanyl, cyclopentane, cyclohexyl, aryl, heteroaryl;
[0112] R 13 Each is independently selected from the following group: methyl, trifluoromethyl, difluoromethyl, deuterated methyl, C2-C6 straight chain alkyl, isopropyl, tert-butyl, isobutyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C4-C6 oxacycloalkyl, C4-C6 oxacycloalkylmethyl, aryl, heteroaryl, benzyl;
[0113] The remaining groups are as defined above.
[0114] Another aspect of the present invention provides a prodrug pharmaceutical composition, which comprises: (i) a therapeutically effective amount of a compound of formula I as described in the first aspect of the present invention, or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable carrier.
[0115] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. DETAILED DESCRIPTION
[0116] After long-term and in-depth research, the inventors prepared a class of compounds having the structure shown in Formula I, and found that they have the activity of inhibiting KRAS-effector protein-protein interactions. And the compounds have an inhibitory effect on a series of KRAS-effector protein-protein interactions at extremely low concentrations (as low as ≤100nmol / L), and the inhibitory activity is quite excellent, so they can be used to treat diseases related to KRAS-effector protein-protein interactions, such as tumors. Based on the above findings, the inventors have completed the present invention.
[0117] the term
[0118] As used herein, the term "C1-C6 alkyl" refers to a straight or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, or the like, and "C1-C3 alkyl" and the like have similar definitions.
[0119] The term "C1-C6 alkoxy" refers to a straight or branched alkoxy group having 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, or the like, and "C1-C3 alkoxy" and the like have similar definitions.
[0120] In the present invention, the terms "comprising", "including" or "including" indicate that various components can be used together in the mixture or composition of the present invention. Therefore, the terms "consisting mainly of" and "consisting of" are included in the term "comprising".
[0121] In the present invention, the term "pharmaceutically acceptable" ingredient refers to a substance that is suitable for use in humans and / or animals without excessive adverse side effects (such as toxicity, irritation and allergic reaction), that is, has a reasonable benefit / risk ratio.
[0122] In the present invention, the term "effective amount" refers to the amount of a therapeutic agent to treat, alleviate or prevent a target disease or condition, or to an amount that exhibits a detectable therapeutic or preventive effect. The exact effective amount for a subject depends on the subject's size and health, the nature and extent of the condition, and the therapeutic agent and / or combination of therapeutic agents selected for administration. Therefore, it is useless to specify an exact effective amount in advance. However, for a given condition, the effective amount can be determined by routine experimentation, which a clinician is able to judge.
[0123] In the present invention, the term "prodrug" refers to a prodrug, a drug precursor, or a prodrug, which refers to a compound that has no or low in vitro protein-interaction enzyme activity against KRAS mutants after chemical structure modification, and releases a highly active drug through enzymatic action or non-enzymatic chemical reaction in vivo to exert its efficacy.
[0124] As used herein, unless otherwise specified, the term "substituted" means that one or more hydrogen atoms on the group are replaced by a substituent selected from the group consisting of halogen, unsubstituted or halogenated C1-C6 alkyl, unsubstituted or halogenated C2-C6 acyl, unsubstituted or halogenated C1-C6 alkyl-hydroxy.
[0125] Unless otherwise specified, in the present invention, all compounds appearing are intended to include all possible optical isomers, such as single chiral compounds, or mixtures of various chiral compounds (i.e., racemates). Among all compounds of the present invention, each chiral carbon atom can be optionally in R configuration or S configuration, or a mixture of R configuration and S configuration.
[0126] The term "cycloalkyl" includes saturated and partially unsaturated cycloalkyl groups having 3 to 12 carbons, for example 3 to 8 carbons, and as a further example 3 to 6 carbons, wherein the cycloalkyl is optionally substituted with one or more. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl and cyclooctyl. The term "cycloalkyl" also includes bridged cycloalkyl groups, for example bicyclo[1.1.1]pentyl.
[0127] As used herein, the term "aryl" group is a C6-C 14 Aromatic moiety, which is optionally substituted by one or more R6 or one or more R7 as defined herein. As an example, aryl is C6-C10 aryl. Examples of aryl include, but are not limited to, phenyl, naphthyl, anthracenyl, fluorenyl and dihydrobenzofuranyl. "Aryl" also refers to a bicyclic or tricyclic ring system, wherein one or both rings of the aromatic ring system can be saturated or partially saturated, respectively, and wherein if the ring system includes two saturated rings, the saturated rings can be fused or spirocyclic, but the connection position with the rest of the compound is on the aryl moiety.
[0128] A "heterocyclyl" or "heterocyclic" group is a ring structure having 3 to 12 atoms, such as 4 to 8 atoms, wherein one or more atoms are selected from the group consisting of N, O and S, wherein the ring N atoms can be oxidized to NO, and the ring S atoms can be oxidized to SO or SO2, and the remaining ring atoms are carbon. A heterocyclyl can be a monocyclic, bicyclic, spirocyclic or bridged ring system. The heterocyclyl or heterocycle can be partially or fully unsaturated, and when the heterocyclyl is a partially unsaturated (i.e., partially non-aromatic) structure, the attachment site of the heterocyclyl or heterocycle can be located on a fully or partially saturated ring or on an aromatic ring.
[0129] The term "heteroaryl" refers to a group having 5 to 14 ring atoms, preferably 5, 6, 9 or 10 ring atoms; and in addition to carbon atoms, each ring has one to three heteroatoms selected from N, O and S. "Heteroaryl" also refers to a bicyclic ring system in which each ring has, in addition to carbon atoms, one to three heteroatoms selected from N, O and S, wherein one of the ring systems may be saturated or partially saturated.
[0130] The term "halogen" refers to F, Cl, Br and I.
[0131] As used herein, the term "compound of the present invention" refers to a compound of Formula I. The term also includes various crystalline forms, pharmaceutically acceptable salts, hydrates or solvates of the compound of Formula I.
[0132] As used herein, the term "pharmaceutically acceptable salt" refers to a salt formed by a compound of the present invention and an acid or base that is suitable for use as a drug. Pharmaceutically acceptable salts include inorganic salts and organic salts. A preferred class of salts is a salt formed by a compound of the present invention and an acid. Suitable acids for forming salts include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, benzenesulfonic acid, benzenesulfonic acid, and acidic amino acids such as aspartic acid and glutamic acid.
[0133] Preparation of small GTPase KRAS mutant inhibitors
[0134] Once the structures of the compounds of the present invention are known, the compounds or prodrugs involved in the present invention can be prepared from commercially available reagents using the synthetic methods and reaction schemes described herein, or using other reagents and conventional methods well known to those skilled in the art.
[0135] For example, the compound of reaction formula A, Formula I can be prepared and synthesized according to formula A. In step a, 4,6-dichloronicotinic acid ethyl ester (1) is reacted with 2,4-dimethoxybenzylamine to generate intermediate (2). In step b, intermediate 2 is treated with hydrochloric acid / dioxane to remove the benzyl group to obtain 4-amino, 6-chloronicotinic acid ethyl ester (3). In step c, 4-amino, 6-chloronicotinic acid ethyl ester (3) is reacted with 2,2,2-trichloroacetyl isocyanate to obtain intermediate (4). In step d, intermediate (4) is treated with ammonia methanol solution to obtain a cyclized core intermediate (5), 7-chloropyrido [4,3-d] pyrimidine dione. In step e, 7-chloropyrido [4,3-d] pyrimidine dione is reacted with phosphorus oxychloride to convert into intermediate (6). In step f, the 2,4,7-trichloropyridopyrimidine intermediate (6) reacts with a tert-butoxycarbonyl protected diazabicyclooctane to generate an intermediate (7). In step g, the intermediate 7 reacts with a nucleophilic reagent HQ-R4 to generate a nucleophilic substitution product of Q-R4, namely, an intermediate (8). In step h, the intermediate (8) reacts with trifluoromethanesulfonic anhydride or zinc difluoromethanesulfinate to generate an intermediate (9). The former reaction conditions are usually carried out at room temperature under LED light irradiation, and the latter reaction conditions are generally carried out in a mixed solution of TFA, FeCl2 in DMSO; H2O, TBHP is added dropwise, and reacted at room temperature. In step i, the intermediate (9) reacts with a boric acid reagent or a trialkyl substituted tin reagent (these two types of reactions are respectively called Suzuki Cross Coupling and Stille Cross Coupling) to generate a carbon-carbon coupling intermediate (10) (or product). In step j, the intermediate (10) is subjected to acidic conditions (usually TFA / dichloromethane) to remove the tert-butyl formate to finally generate compound Formula I.
[0136]
[0137] For another example, the compound of Formula IA can be prepared and synthesized according to Formula B. In step a, 7-chloro, 8-fluoropyrido[4,3-d]pyrimidinedione (11) is reacted with phosphorus oxychloride to generate an intermediate 2,4,7-trichloro-8-fluoropyridopyrimidine intermediate (12). In step b, intermediate 12 is reacted with diazabicyclooctane protected by tert-butoxycarbonyl to generate intermediate (13). In step c, intermediate 13 is reacted with nucleophilic reagent HQ-R4 to generate intermediate 14, a nucleophilic substitution product of Q-R4. In step d, intermediate (14) is reacted with boric acid or boric ester reagent or trialkyl substituted tin reagent (these two types of reactions are respectively called Suzuki Cross Coupling and Stille Cross Coupling) to generate carbon-carbon coupling intermediate (15) (or product). In step e, the intermediate (15) is subjected to acidic conditions (usually TFA / dichloromethane) to remove the tert-butyl formate to finally generate compound Formula IA.
[0138]
[0139] For another example, the compound of reaction formula C, Formula IA can be prepared and synthesized according to formula B. In step a, 7-chloro, 8-fluoropyrido [4,3-d] pyrimidine dione (11) is reacted with phosphorus oxychloride to generate an intermediate 2,4,7-trichloro-8-fluoropyrido pyrimidine intermediate (12). In step b, intermediate 12 is reacted with diazabicyclooctane protected by tert-butoxycarbonyl to generate intermediate (13). In step c, intermediate 13 is reacted with nucleophilic reagent HZ-R4' to generate intermediate 14a protected by 2-Cl, and compound 14a is reacted with boric acid or boric ester reagent or trialkyl substituted tin reagent (these two types of reactions are respectively called Suzuki Cross Coupling and Stille Cross Coupling) to generate carbon-carbon coupling intermediate 14b. In step e, intermediate (14b) is reacted with nucleophilic reagent HQ-R4 to generate intermediate (15) (or product) of nucleophilic substitution product of Q-R4. In step e, the intermediate (15) is subjected to acidic conditions (usually TFA / dichloromethane) to remove the tert-butyl formate to finally generate compound Formula IA.
[0140]
[0141] The compound of Formula II can be prepared and synthesized according to the method shown in Formula D.
[0142] In step a, intermediate 16 reacts with a nucleophile 1-(aminomethyl)-N,N-disubstituted (R'1)-cyclobutane-1-amine to produce a nucleophilic substitution product intermediate 17. In step b, intermediate 17 reacts with a nucleophile HQ-R4 to produce a right-side chain nucleophilic substitution product intermediate 18 of Q-R4. In step c, intermediate (17) reacts with a boronic acid or boronic ester reagent to produce a carbon-carbon coupling intermediate (19) (or product). In step d, intermediate (19) is de-tert-butylated under acidic conditions (usually TFA / dichloromethane) to finally produce compound Formula II.
[0143]
[0144] Other compounds can be prepared by replacing the corresponding starting material fragments using the methods described in the examples of the present invention.
[0145] Pharmaceutical compositions, prodrugs and methods of administration
[0146] Since the compounds of the present invention have excellent inhibitory activity against KRAS mutants, the compounds of the present invention and their various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and pharmaceutical compositions containing the compounds of the present invention as the main active ingredient can be used to treat, prevent and alleviate diseases associated with the activity or expression of KRAS mutants.
[0147] KRAS mutants not only refer to G12D mutants, but also include G12V, G12S, G13D and G12C mutants.
[0148] In a preferred embodiment, the above-mentioned disease associated with KRAS mutant activity or expression is selected from the following group:
[0149] Heart: sarcomas (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma, and teratoma;
[0150] Lung: bronchial carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, enchondroma, hamartoma, mesothelioma;
[0151] Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, vipoma), small intestine (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); genitourinary tract : Kidney (adenocarcinoma, Wilms' tumor (Nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatoid tumor, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma;
[0152] Biliary tract: gallbladder cancer, ampullary cancer, bile duct cancer;
[0153] Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulocyte sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteocartilaginous exostosis), benign enchondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma and giant cell tumor; Nervous system: skull (osteomas, hemangiomas, granulomas, xanthomas, osteitis deformans), meninges (meningiomas, meningosarcomas, gliomas), brain (astrocytomas, medulloblastomas, gliomas, ependymomas, germ cell tumors (pinealomas), glioblastoma multiforme, oligodendrogliomas, schwannomas, retinoblastomas, congenital tumors), spinal neurofibromas, meningeal Tumor, glioma, sarcoma); Gynecology: uterus (endometrial cancer (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa cell-theca tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tube (carcinoma), breast cancer, ovarian cancer; Hematology: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma);
[0154] Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi sarcoma, dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; and Adrenal gland: neuroblastoma.
[0155] In a most preferred embodiment, the cancer is non-small cell lung cancer, small cell lung cancer, colorectal cancer, rectal cancer or pancreatic cancer.
[0156] The prodrug of the present invention, the pharmaceutical composition comprises a safe and effective amount of the compound of the present invention or a pharmacologically acceptable salt thereof and a pharmacologically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Usually, the pharmaceutical composition contains 1-2000 mg of the compound of the present invention / dose, more preferably, contains 5-600 mg of the compound of the present invention / dose. Preferably, the "one dose" is a capsule or tablet.
[0157] "Pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0158] The administration method of the compound or pharmaceutical composition of the present invention is not particularly limited, and representative administration methods include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.
[0159] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
[0160] Solid dosage forms such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients.
[0161] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.
[0162] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0163] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures of these substances, and the like.
[0164] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0165] Dosage forms for topical administration of the compounds of the invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required as necessary.
[0166] The compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
[0167] When using the pharmaceutical composition, a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage during administration is a pharmaceutically effective dosage. For a person weighing 60 kg, the daily dosage is usually 1 to 1200 mg, preferably 5 to 600 mg. Of course, the specific dosage should also take into account factors such as the route of administration and the health status of the patient, which are all within the skill range of a skilled physician.
[0168] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.
[0169] Preparation Example 1
[0170]
[0171]
[0172] Step a:
[0173] At room temperature, the raw materials 1-1 (10.0 g) was dissolved in acetonitrile (100 ml), and N,N-diisopropylethylamine (9.4 g) and DMBNH2 (9.0 g) were added in sequence. The reaction solution was stirred at 25°C for 2 hours. After the reaction was complete, water (200 ml) was added to the mixture and extracted three times with ethyl acetate (200 ml). The organic layers were combined, washed with saturated brine (200 ml), and the organic layer was dried over anhydrous sodium sulfate. The crude product was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 15%-30%) to obtain a yellow solid. 1-2 (13.0 g).
[0174] LCMS: m / z 351 (M+H)+ .
[0175] Step b:
[0176] At room temperature, the intermediate 1-2 (13.0 g) was dissolved in hydrochloric acid / dioxane (130 ml) and stirred at 80°C for 16 hours. After the reaction was complete, the reaction solution was concentrated to dryness. Toluene was then added and concentrated, and the reaction was repeated three times to obtain a yellow solid. 1-3 (9.0 g).
[0177] LCMS: m / z 201 (M+H) + .
[0178] Step c:
[0179] At 0℃, the intermediate 1-3 (9.0 g) was dissolved in tetrahydrofuran (100 ml), and triethylamine (4.5 g) and trichloroisocyanate were added in sequence. 4 (10.9 g), stirred at 0°C for 2 hours. After the reaction was complete, then added under stirring for 2 hours. After the reaction was complete, water (200 ml) was added to the mixture and extracted three times with ethyl acetate (100 ml). The organic layers were combined, washed with saturated brine (100 ml), and the organic layer was dried over anhydrous sodium sulfate. The organic phase was concentrated to dryness to obtain a yellow oil 1-5 (9.5 grams).
[0180] LCMS: m / z 390 (M+H) + .
[0181] Step d:
[0182] At room temperature, the intermediate 1-5 (9.5 g) was dissolved in ammonia methanol (30 ml) and stirred at room temperature for 16 hours. After the reaction was complete, the reaction solution was concentrated to dryness, methanol (20 ml) was added to the crude product, solid precipitated, and then filtered to collect the solid to obtain a yellow solid 1-6 (6.5 grams).
[0183] LCMS: m / z 198 (M+H) + .
[0184] Step e:
[0185] At room temperature, the intermediate 1-6 (2.0 g) was dissolved in phosphorus oxychloride (20 ml), and N,N-diisopropylethylamine (5.0 ml) was added to react at 120°C for 2 hours. After the reaction was complete, the mixture was concentrated under reduced pressure, and the crude product was purified by neutral alumina column chromatography (ethyl acetate as eluent) to obtain a black oily substance. 1-7 , (1.8 grams).
[0186] LCMS: m / z 234 (M+H) + .
[0187] Step f:
[0188] At room temperature, the intermediate 1-7 (1.8 g) was dissolved in dichloromethane (20 ml), and then (1R, 5S)-3,8-diazacyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester 1-8 (1.3 g) and N,N-diisopropylethylamine (3.81 ml) were added in sequence. Stir at room temperature for 1 hour. After the reaction was complete, water (30 ml) was slowly added and extracted three times with dichloromethane (20 ml). The organic phase was washed with saturated brine (30 ml), then dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 10:1-2:1) to obtain a yellow solid. 1-9 , (0.8 g).
[0189] LCMS: m / z 410 (M+H) + .
[0190] Step g:
[0191] At room temperature, the intermediate 1-9 (0.8 g) was dissolved in tetrahydrofuran (15 ml), and then (2R, 7aS)-2-fluorotetrahydro-1H-pyridine-7a(5H)methanol 1-10 (0.62 g) and cesium carbonate (1.91 g) were added in sequence. Stir at 70°C for 3 hours. After the reaction was complete, water (30 ml) was slowly added and extracted three times with ethyl acetate (20 ml). The organic phase was washed with saturated brine (30 ml), then dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column (dichloromethane: methanol = 50: 1-10: 1) to obtain yellow solid Preparation Example 1 (0.5 g).
[0192] LCMS: m / z 533 (M+H) + .
[0193] Preparation Example 2
[0194]
[0195] At room temperature, the intermediate preparation example 1 (500 mg) was dissolved in 1,2, dichloroethane (12 ml), and then dichlorotris(2,2'-bipyridine)ruthenium (II) hexahydrate (69 mg), pyridine (0.275 ml), and trifluoromethanesulfonic anhydride (0.32 ml) were added in sequence. Stir at room temperature for 2 hours under LED light. After the reaction was completed, water (20 ml) was slowly added and extracted three times with dichloromethane (10 ml). The organic phase was washed with saturated brine (20 ml), then dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product, which was purified by preparative column chromatography (dichloromethane: methanol = 10: 1) to obtain yellow solid preparation example 2 (75 mg).
[0196] LCMS: m / z 601 (M+H) + .
[0197] Preparation Example 3
[0198]
[0199] The synthesis of Preparation Example 3 was carried out under similar conditions to Preparation Example 1, yielding yellow solid 1 (70 mg).
[0200] LCMS: m / z 533 (M+H) + .
[0201] Preparation Example 4
[0202]
[0203] The synthesis of Preparation 4 was carried out under similar conditions to Preparation 2 to obtain the pure intermediate as a yellow solid (49 mg).
[0204] LCMS: m / z=601.1 (M+H) + .
[0205] Preparation Example 5 and Preparation Example 6
[0206]
[0207] To a solution of Preparation Example 1 (1.0 g, 1.88 mmol) and TFA (342.96 mg, 1.88 mmol) in DMSO (30 mL) at room temperature, a solution of bis(((difluoromethyl)sulfinyl)oxy)zincy (1.65 g, 5.64 mmol) and FeCl2 (118.3 mg, 0.94 mmol) in H2O (5 mL) was added, and TBHP (70% purity, 241.93 mg) was added dropwise to the resulting mixture. The mixture was stirred at room temperature for 15 h. LCMS showed that the product was detected, 10 mL of water was added and extracted with EtOAc (10 mL*3), the organic layer was dried over anhydrous Na2SO4, filtered and evaporated in vacuo to give a crude product, which was purified by silica gel column with MeOH:DCM:=0-3% to give a yellow solid Preparation Example 5 (70 mg).
[0208] LCMS: m / z [M+H] + =583.2.
[0209] Preparation Example 6 can be prepared by a similar method to Preparation Example 5.
[0210] Preparation Example 7
[0211]
[0212] Step a:
[0213] 7-1 (2.0 g, 9.1 mmol) was dissolved in methanol (25), and sodium borohydride (0.67 g, 17.7 mmol) was added in batches at 0°C. The reaction was then warmed to room temperature and stirred for 1 hour. TLC showed that the reaction was complete, and the mixture was poured into a saturated ammonium chloride solution (10 mL) and extracted with DCM (10 mL*3). The organic layer was washed with water (10 ml) and a saturated sodium chloride aqueous solution (10 mL), dried over anhydrous magnesium sulfate, filtered, and the organic phase liquid was then dried under reduced pressure to obtain a white solid 7-2 (1.95 g).
[0214] 1H NMR (400MHz, CDCl3) δ7.34 (ddd, J=8.8, 4.2, 1.9Hz, 1H), 7.05 (dd, J=17.7, 8.9Hz, 1H), 4.85 (d, J=2.2Hz, 2H).
[0215] Step b:
[0216] 7-2 (1.95 g, 8.8 mmol) was dissolved in THF (20 ml), and DIEA (1.8 ml, 10.3 mmol) was added, the mixture was cooled to 0 ° C, and then methanesulfonic anhydride (1.7 g, 9.42 mmol) was added. After stirring at ambient temperature for 16 hours, the mixture was diluted with EtOAc: methyl tert-butyl ether (1: 1) (15 mL) and washed with cold water (20 ml). The layers were separated and the aqueous solution was extracted twice with EtOAc: methyl tert-butyl ether (1: 1) (20 mL * 3). The combined organics were washed with water and saturated sodium chloride aqueous solution, dried over anhydrous magnesium sulfate, filtered, and the organic phase liquid was then spin-dried under reduced pressure to give a yellow oil 7-3 (2.60 g).
[0217] 1H NMR (400MHz, CDCl3) δ7.41–7.35(m,1H),7.15(q,J=8.8Hz,1H),5.37(d,J=1.4Hz,2H),3.07(d,J=0.6Hz,3H).
[0218] Step c:
[0219] A mixture of compound 7-3 (2.6 g, 8.2 mmol) and potassium cyanide (0.61 g, 9.03 mmol) in ethanol (20 ml) and water (4 ml) was refluxed for 30 minutes and then cooled to ambient temperature. The solvent was removed in vacuo and the residue was suspended in DCM (20 mL). The mixture was washed with water, saturated sodium bicarbonate solution and saturated sodium chloride aqueous solution. The organic matter was dried over magnesium sulfate, filtered, and the organic phase liquid was then spin-dried under reduced pressure. The crude product was purified by silica gel flash column chromatography, eluted with 10-100% DCM / hexane to obtain 7-4 (1.8 g).
[0220] 1H NMR (400MHz, CDCl3) δ7.40 (ddd, J=9.0, 4.4, 2.1Hz, 1H), 7.13 (dd, J=17.4, 9.1Hz, 1H), 3.89 (d, J=1.9Hz, 2H).
[0221] Step d:
[0222] A solution of 7-4 (1.8 g, 7.75 mmol) in DMF (20 ml) was cooled in an ice bath, and then potassium tert-butoxide (0.930 g, 8.12 mmol) was added to the solution in batches, the mixture was stirred for 10 minutes (the reaction turned dark red), and ethoxycarbonyl isothiocyanate (0.98 mL, 8.14 mmol) was added dropwise. The reaction mixture was stirred at ambient temperature for 1 hour and then heated at 100 ° C for 30 minutes. The mixture was then cooled in an ice bath for 10 minutes, and water (50 ml) was slowly added under stirring. The resulting precipitate was collected by filtration, rinsed with water and hexane, and then dried to obtain 7-5 (2.45 g) for direct use in the next step.
[0223] Step e:
[0224] In a solution of 7-5 (2.45 g, 7.2 mmol) in DMSO (10 milliliters), 5N NaOH solution (0.8 milliliter, 40 mmol) was added and refluxed for 7 hours. The mixture was cooled to room temperature and treated with cold water while stirring vigorously. The resulting precipitate was collected by filtration, washed with water, and dried to give white solid compound 7-6 (1.55 g).
[0225] 1H NMR (400MHz, DMSO-d6) δ8.22 (s, 2H), 7.51-7.48 (dd, J = 4.0, 8.0Hz, 1H), 6.96 (t, J = 8.0Hz, 1H).
[0226] Step f:
[0227] Boc2O (1.96 g, 8.71 mmol) was added to a solution of compound 7-6 (2 g, 7.9 mmol), DIEA (2.1 mL, 12 mmol) and DMAP (80 mg, 0.655 mmol) in THF (27 mL) and DMF (4 mL). The mixture was stirred under nitrogen for 4 hours at room temperature. The reaction mixture was diluted with aqueous sodium bicarbonate solution and ethyl acetate (1:1) (20 mL) and then stirred for 10 minutes. The resulting precipitate was collected by filtration, washed with cold EtOAc (20 mL), dried, and further extracted with EtOAc (20 mL*2). The organic extract was washed with water (20 mL) and saturated aqueous sodium chloride solution (20 mL), dried over magnesium sulfate, filtered, and then the organic phase liquid was spin-dried under reduced pressure and purified by silica gel flash chromatography column, eluted with 20-100% DCM / hexane to obtain 7-7 (1.2 g, 3.2 mmol).
[0228] 1H NMR (400MHz, DMSO-d6) δ 11.78 (s, 1H), 7.69-7.66 (dd, J = 4.0, 8.0Hz, 1H), 7.20 (t, J = 8.0Hz, 1H), 1.54 (s, 9H).
[0229] Step g:
[0230] Intermediate 7-7 (1.60 g, 4.14 mmol) and bis-neopentyl glycol diboronate 7-8 (3.70 g, 15.7 mmol) were dissolved in 1,4-dioxane (30 ml). Potassium acetate (1.2 g, 12.4 mmol) was added and replaced with nitrogen three times. DPEpHosPdC12 (0.3 g, 0.42 mmol) was added and heated at 95 °C for 1 hour. The mixture was then cooled to room temperature and filtered. The reaction solution was concentrated to 10 mL under reduced pressure, diluted with heptane (20 mL), stirred for 10 minutes, and then filtered through celite, rinsed with heptane and heptane: methyl tert-butyl ether (1:1). The filtrate was concentrated, dissolved in minimal DCM (10 ml), and filtered through a silica gel pad, rinsed with ethyl acetate: heptane (1:1). The filtrate was rinsed with saturated ammonium chloride solution and saturated sodium chloride aqueous solution, respectively. The organics were dried over magnesium sulfate, filtered, and the organic phase liquid was then spin dried under reduced pressure and purified by flash column chromatography on silica gel eluting with 5-50% (20% acetone in DCM) / hexanes to give the boronate Preparation 7 as a white solid (1.30 g, 3.2 mmol).
[0231] 1H NMR(DMSO-d6)d 11.6(s,1H),7.61(m,1H),7.20(m,1H),3.78(s,4H),1.54(s,9H),1.03(s,6H).
[0232] Similar borate esters such as Preparation Example 7 'and the like can be prepared by a similar method as in Preparation Example 7.
[0233]
[0234] Preparation Example 8
[0235]
[0236] Step a:
[0237] At -78 ° C and under nitrogen protection, 8-1 (120 mg, 0.258 mmol) was dissolved in dichloromethane (5 mL), and then BBr3 (1N, 1.29 mL) was added dropwise, and the reaction solution was gradually warmed to room temperature. LCMS showed that the reaction was complete and the product was generated. The reaction solution was directly concentrated under reduced pressure to obtain the crude product 8-2, which could be directly used in the next step without separation.
[0238] LCMS: m / z=439.9 (M+H) + .
[0239] Step b:
[0240] Boc2O (75.21 mg, 0.342 mmol) and DIEA (110.5 mg, 0.855 mmol) were added to a solution of 8-2 (100 mg, 0.285 mmol) in dichloromethane (2 mL), and the reaction solution was stirred at 20°C for 15 h. LCMS showed that the raw materials had reacted completely and the product was generated. The reaction solution was treated conventionally and the obtained product was further purified by pre-TLC (PE:EA=3:1) to obtain a white solid 8-3 (40 mg).
[0241] LCMS: m / z=452.2 (M+H) + .
[0242] Step c:
[0243] At 0°C, DAST (28.36 mg, 0.176 mmol) was added to a solution of 8-3 (40 mg, 0.088 mmol) in dichloromethane (0.5 mL), and the reaction solution was stirred at 0°C for 1 h. LCMS showed that the raw materials were reacted and the product was generated. The reaction solution was quenched with a saturated aqueous NaHCO3 solution (2 mL) and extracted with EtOAc (10 mL*3). The collected organic matter was dried under reduced pressure to obtain a white solid Preparation Example 8 (13.3 mg).
[0244] LCMS: m / z=454.1 (M+H) + .
[0245] Preparation Example 9
[0246]
[0247] Step a
[0248] At room temperature, 9-1 (2 g, 13.87 mmol) was added to a 100 mL single-mouth bottle, DCM (10 mL) was added to dissolve, DMF (0.11 mL) was added, and oxalyl chloride (COCl) 2 (2 mL, 20.81 mmol, 1.5 eq.) was added at 0 degrees Celsius. After the reaction solution was stirred for 2 hours, the reaction solution was dried under reduced pressure, and the unreacted oxalyl chloride was removed with toluene. The reaction was repeated three times to obtain the intermediate 9-2, which was directly used in the next step.
[0249] Step b
[0250] The crude product 9-2 from the first step was dissolved in THF (15 mL), DIEA (30 mL) was added at 0 degrees Celsius, and 9-3 (3.11 g, 20.81 mmol, 1.5 eq.) was added. The mixture was reacted at 25°C for 17 hours under nitrogen protection. After the reaction was complete, it was extracted 3 times with DCM (20 mL), and the organic phase was washed three times with water (20 mL) and saturated brine (20 mL). The organic phase was dried over anhydrous sodium sulfate, and then the organic phase liquid was dried under reduced pressure. The crude product was purified by silica gel column chromatography (PE: EA = 1: 2) to obtain an off-white oil 9-4 (1 gram).
[0251] LCMS: m / z=240.1 (M+H) +
[0252] Step c
[0253] At room temperature, 9-4 (400 mg, 1.67 mmol, 1.0 eq.) was added to a 50 mL single-mouth bottle, THF (5 mL) was added to dissolve, and LiAlH4 tetrahydrofuran solution (6.68 mL, 3.34 mmol, 2.0 eq., 1 M in THF) was slowly added at 0 degrees Celsius, and the mixture was reacted at 25°C for 3 hours. After the reaction was complete, anhydrous sodium sulfate and ether were added and stirred overnight. The reaction solution was filtered and dried under reduced pressure to obtain an off-white solid 9-5 (300 mg).
[0254] H-NMR: 1HNMR (400MHz, DMSO-d6) δ4.70 (d, J = 34.1Hz, 1H), 3.49 (d, J = 10.2Hz, 2H), 3.43–3.38 (m, 4H), 3. 09(s,2H),2.26(s,2H),1.83–1.74(m,2H),1.71–1.62(m,2H),0.39–0.31(m,2H),0.25(q,J=4.0Hz,2H).
[0255] Step d
[0256] At room temperature, 9-6 (300 mg, 0.7 mmol, 1.0 eq), 9-5 (280 mg, 1.4 mmol, 2.0 eq), Cs2CO3 (684 mg, 2.1 mmol, 3.0 eq) were added to a 25 ml single-mouth bottle and dissolved in THF (5 ml). The mixture was reacted at 70°C for 12 hours. After the reaction was complete, it was filtered and the filtrate was dried by spin drying. Then it was extracted 3 times with DCM (10 ml), and the organic phase was washed three times with water (10 ml) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, and then the organic phase liquid was spin dried under reduced pressure. The crude product was purified by silica gel column chromatography (DCM: MeOH = 10: 1) to obtain yellow solid Preparation Example 9 (150 mg).
[0257] Preparation Example 10 and Preparation Example 11
[0258]
[0259] Step a:
[0260] At zero degrees, the raw material 10-1 (1.0 g, 4.64 mmol) was dissolved in phosphorus oxychloride (10 ml), and N,N-diisopropylethylamine (4.0 mL, 23.2 mmol) was added, and the mixture was reacted at 120°C for 3 hours. After the reaction was complete, the mixture was cooled and concentrated under reduced pressure, and the crude product was directly used in the next step to obtain a black oil 10-2 (1.17 g).
[0261] Step b:
[0262] Under room temperature, the intermediate 10-2 (1.17 g, 4.6 mmol) was dissolved in dichloromethane (20 ml) and N, N-diisopropylethylamine was added to adjust the pH to 7, and then N, N-diisopropylethylamine (4.0 mL, 22.98 mmol) and 10-3 (1.89 g, 11.49 mmol) were added in sequence. Stir at room temperature for 2 hours. After the reaction was complete, water (300 ml) was slowly added and extracted three times with dichloromethane (200 ml). The organic phase was washed with saturated brine (200 ml), then dried over anhydrous sodium sulfate, and then the organic phase liquid was spin-dried under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 10: 1) to obtain a red solid 10-4 (450 mg).
[0263] LCMS: m / z=317.1 (M+H) + .
[0264] Step c:
[0265] At room temperature, the intermediate 10-4 (100 mg, 0.29 mmol) was dissolved in tetrahydrofuran (4 ml), and then the chiral compound butterfly alcohol 1-10 (92 mg, 0.58 mmol) and cesium carbonate (283 mg, 0.87 mmol) were added in sequence. Stir at 70 ° C for 17 hours. After the reaction was complete, water (100 mL) was slowly added and extracted three times with ethyl acetate (150 mL). The organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and then the organic phase liquid was dried under reduced pressure. The crude product was purified by silica gel column (0-25% methanol in dichloromethane) to obtain yellow solid Preparation Example 10 (20 mg).
[0266] LCMS: m / z=467.2 (M+H) +
[0267] Preparation Example 11 can be prepared by a similar method to Preparation Example 10.
[0268] Example 1
[0269]
[0270] Step a
[0271] To a solution of intermediate preparation example 2 (70 mg, 0.117 mmol) in toluene (0.6 mL) was added borate preparation example 7 (141.80 mg, 0.351 mmol), DPEpHosCl2 (16.75 mg, 0.0234 mmol) and Cs2CO3 (114.36 mg, 0.351 mmol) were added under N2, and the mixture was stirred at 120°C for 1 hour under microwave conditions. Thin layer chromatography of the mixed solution showed that the reaction was complete. The reaction mixture was cooled and filtered, the reaction mixture was diluted with water (10 mL), extracted with EtOAc (20 mL*3), and the extracted organic phase was dried under reduced pressure to give a crude product. Further purification by pre-HPLC (eluted with CH3CN:0.03% HCCOH), 10% CH3CN to 95% CH3CN, gave 1-1 (5.42 mg) as a white solid.
[0272] LCMS: [M+H] + =857.2.
[0273] Step b
[0274] TFA (0.2 mL) was added to a solution of 1-1 (40 mg, 0.047 mmol) in DCM (1 mL) at 20°C, and the mixture was stirred at 20°C for 1 h. The reaction solution was spin-dried under reduced pressure. The residue was purified by Pre-HPLC (eluted with CH3CN:0.03% HCOOH) 10% CH3CN to 95% CH3CN to give Example 6 (12.21 mg) as a white solid.
[0275] LCMS: [M+H] + =657.3.
[0276] 1H NMR(400MHz,MeOD)δ9.26(s,1H),7.22(dd,J=8.3,5.0Hz,1H),7.07–6.91(m,1H),5.44(d,J=51.6Hz,1H),4.53(dt,J=22.5,11.5Hz,3H) ,3.98(t,J=13.6Hz,3H),3.76(d,J=13.2Hz,1H),3.58(d,J=24.0Hz,3H),3.30-3.25(m,2H),2.60–2.14(m,5H),1.95(d,J=37.9Hz,5H).
[0277] Example 2
[0278]
[0279] The preparation of Example 2 can refer to the similar method of Example 1 to obtain Example 2 (1.89 mg) as a white solid by carbon-carbon coupling of Preparation Example 4 and Preparation Example 7 and then hydrolysis with trifluoroacetic acid.
[0280] LCMS: m / z=657.1 (M+H) + .
[0281] 1 H NMR (400MHz, MeOD) δ9.28 (s, 1H), 8.47 (s, 1H), 7.25 (dd, J = 8.3, 5.0Hz, 1H), 7.03 (t ,J=8.9Hz,1H),5.45(d,J=52.1Hz,1H),4.60–4.50(m,3H),4.01(d,J=13.6Hz,3H), 3.77(d,J=10.4Hz,1H),3.59(dd,J=22.2,8.7Hz,3H),3.23(dd,J=29.2,18.9Hz,2H ),2.59–2.41(m,2H),2.35–2.27(m,1H),2.25–2.14(m,2H),1.96(d,J=37.5Hz,5H).
[0282] Example 3
[0283]
[0284] Step a
[0285] Under nitrogen protection, 3-2 (11.5 mg, 0.028 mmol), cesium carbonate (18 mg, 0.056 mmol) and DPEpHosPdCl2 (5.3 mg, 0.0074 mmol) were added to a solution of compound 3-1 (11.4 mg, 0.0185 mmol) in N,N-dimethylformamide (DMF) (0.5 mL) under nitrogen protection. The mixture was stirred under microwave at 120 ° C for 1 hour. LCMS showed that the reaction was complete, and the reaction solution was cooled and then filtered. The mixture was dried under reduced pressure to obtain a crude product, and the crude product was obtained by pre-HPLC (using formic acid method) to obtain a white solid 3-3 (5.3 mg).
[0286] LCMS: m / z [M+H]+ = 871.2.
[0287] Step b
[0288] To a solution of intermediate 3-3 (30.0 mg, 0.034 mmol) in dichloromethane (1.0 mL) was added TFA (0.2 mL) and the mixture was stirred at 25 °C for 1 hour. LCMS showed that the product was detected. The reaction was then concentrated to give the crude product and Pre-HPLC (using formic acid method) gave Example 3 (5.71 mg) as a white solid.
[0289] LCMS: m / z [M+H]+ = 671.1.
[0290] 1H NMR(400MHz,MeOD)δ9.29(s,1H),7.25(dd,J=8.3,5.0Hz,1H),7.04(t,J=8.9Hz,1H),5.45 (d,J=53.6Hz,1H),4.95(s,1H),4.68–4.45(m,3H),4.20(d,J=14.9Hz,2H),4.04(d,J=13. 9Hz,1H),3.86(d,J=13.8Hz,2H),3.68(s,1H),3.61–3.45(m,2H),3.37(s,1H),3.16(d,J= 13.0Hz, 1H), 2.41 (ddd, J=47.1, 28.0, 11.3Hz, 2H), 2.16–1.98 (m, 4H), 1.02–0.79 (m, 4H).
[0291] Example 4
[0292]
[0293] Step a
[0294] At room temperature, to a solution of Preparation Example 5 (10 mg, 0.172 mmol) in DMF (0.5 mL) was added Preparation Example 7 (10.43 mg, 0.0258 mmol) and DPEpHosPdCl2 (2.46 mg, 0.0034 mmol), Cs2CO3 (16.81 mg, 0.516 mmol) under nitrogen protection. The resulting mixture was stirred at 120 ° C for 1 hour in a microwave. LCMS showed that the product was detected, and the mixture was filtered and 10 mL of water was added and extracted with ethyl acetate (10 mL * 3). The organic layer was dried over anhydrous Na2SO4, and the solvent was evaporated under rotary reduced pressure to obtain a crude product, which was purified by pre-HPLC (eluted with CH3CN: 0.001HCOOH / H2O) 10% CH3CN to 95% CH3CN to obtain 4-1 (4.64 mg, 0.0055 mmol) as a white solid.
[0295] LCMS: m / z [M+H] + =839.3.
[0296] Step b
[0297] To a solution of 4-1 (20 mg, 0.0239 mmol) in DCM (1 mL) was added TFA (0.2 mL). The mixture was stirred at 20 °C for 1 hour. LCMS showed that the reaction was complete, and then the reaction was concentrated to give a crude residue which was purified by pre-HPLC (method with formic acid): eluted with CH3CN: 0.001HCOOH / H2O) 10% CH3CN to 95% CH3CN to give Example 4 (2.04 mg, 0.0032 mmol) as a white solid.
[0298] LCMS: m / z [M+H] + =639.3.
[0299] 1H NMR(400MHz,CD3OD)δ9.32(s,1H),7.67–7.27(m,2H),7.14–6.98(m,1H),5.59(d,J=52.9Hz,1H),4.78–4.65(m,2H), 4.23(s,2H),3.94(s,5H),3.50(s,2H),3.15(s,1H),2.80–2.58(m,2H),2.46(s,1H),2.37(s,2H),2.20–1.94(m,5H).
[0300] Example 5
[0301]
[0302]
[0303] Step a
[0304] At 0°C, m-CPBA (8.04 mg, 0.0396 mmol, 85% purity) was added to a solution of Preparation Example 8 (15 mg, 0.033 mmol) in DCM (0.5 mL), and stirred at 0°C for 0.5 h. LCMS showed that the raw materials had reacted completely and the product was generated. The reaction solution was quenched with a saturated aqueous NaHCO3 solution (5 mL) and extracted with EtOAc (10 mL*3). The organic phase was dried over anhydrous Na2SO4 and filtered. The organic phase liquid was concentrated under reduced pressure to obtain 5-1, which was directly used in the next step.
[0305] LCMS: m / z [M+H]+ = 470.1
[0306] Step b
[0307] At 25°C, 1-10 (5.09 mg, 0.032 mmol) was added to a solution of 5-1 (15 mg, 0.032 mmol) in THF (0.5 mL), and stirred at 70°C for 15 h. LCMS showed that the raw materials were reacted and the product was generated. The reaction solution was concentrated and purified by pre-TLC (DCM: MeOH = 10: 1) to obtain a white solid 5-2 (10 mg, 0.0177 mmol).
[0308] LCMS: m / z [M+H]+ = 565.3
[0309] Step c
[0310] At 15°C, the intermediate 5-2 (5 mg, 0.0088 mmol) in DMF (0.5 mL) was added with Preparation Example 7 (1.78 mg, 0.01144 mmol), DPEpHosPdCl2 (0.63 mg, 0.00088 mmol) and Cs2CO3 (8.58 mg, 0.0264 mmol). The mixture was stirred for 1 hour under 120°C microwave reaction conditions. LCMS showed that the reaction was complete. The reaction solution was cooled and filtered, and the mixture was dried under reduced pressure to obtain a crude product, which was purified by pre-HPLC (using formic acid method) to obtain a white solid 5-3 (5.0 mg).
[0311] LCMS: m / z [M+H]+ = 821.3.
[0312] Step d
[0313] At 0°C, TFA (0.2 mL) was added to a solution of 5-3 (6.5 mg, 0.0094 mmol) in dichloromethane (0.6 mL), and the mixture was stirred at 15°C for 1 h. LCMS showed that the raw material was reacted completely and the product was generated. The reaction solution was directly concentrated to obtain a crude product which was further purified by pre-HPLC (using formic acid method) to obtain Example 5 (2.58 mg) as a white solid.
[0314] LCMS: m / z [M+H]+ = 621.2.
[0315] 1 H NMR (400MHz, MeOD) δ9.27(s,1H),7.35(dd,J=8.3,5.4Hz,1H),7.06(t,J=8.8Hz,1H),5.58(d,J=52.5Hz,3H),4.75(dd,J=35.2,12. 5Hz,4H),4.23(s,2H),4.10–3.81(m,5H),3.48(s,1H),2.80–2.54(m,2H),2.47(s,1H),2.36(s,2H),2.04(dd,J=26.2,15.5Hz,5H).
[0316] Example 6
[0317]
[0318] Step a
[0319] Under nitrogen protection, Preparation Example 7 (52 mg, 0.128 mmol), cesium carbonate (63 mg, 0.192 mmol) and DPEpHosPdCl2 (18 mg, 0.0256 mmol) were added to a solution of Preparation Example 10 (30 mg, 0.064 mmol) in N,N-dimethylformamide (1.5 mL) under nitrogen protection. The mixture was stirred under microwave at 120 ° C for 1 hour. LCMS showed that the reaction was complete, and the reaction solution was cooled and filtered. The filtrate was dried under reduced pressure to obtain a crude product, and the crude product was obtained by Pre-TLC and pre-HPLC (using formic acid method) to obtain a white solid 6-1 (7 mg).
[0320] LCMS: [M+H] + =723.3.
[0321] Step b
[0322] To a solution of compound 6-1 (5 mg, 0.0069 mmol) in dichloromethane (1.0 mL) was added TFA (0.2 mL), and the mixture was stirred at 25° C. for 1 hour. LCMS showed that the product was detected. The reaction solution was then concentrated under reduced pressure to obtain a crude product and obtained as a white solid Example 6 (1.44 mg) by pre-HPLC (using formic acid method).
[0323] LCMS: [M+H] + =623.2.
[0324] 1H NMR (400MHz, MeOD) δ9.26 (s, 1H), 7.40 (dd, J = 8.4, 5.1Hz, 1H), 7.06 (t, J = 8.9 Hz,1H),5.45(d,J=52.6Hz,1H),4.55(q,J=11.7Hz,2H),4.17(d,J=16.6Hz,2 H),3.61(d,J=16.4Hz,3H),2.70(s,6H),2.58–2.46(m,1H),2.39(dd,J=27.0 ,9.1Hz,3H),2.25(dd,J=32.8,14.0Hz,6H),2.03(s,1H),1.99–1.90(m,2H).
[0325] Example 7
[0326]
[0327]
[0328] Step a
[0329] At room temperature, Preparation Example 9 (50 mg, 0.085 mmol), Preparation Example 7 (51 mg, 0.127 mmol, 1.5 eq.), DPEpHosPdCl2 (25 mg, 0.034 mmol, 0.4 eq.), Cs2CO3 (83 mg, 0.254 mmol, 3.0 eq.) were added to 8 ml microwave tubes and dissolved in DMF (1 mL), and stirred at 120 degrees Celsius for 1 hour. After the reaction was complete, the reaction mixture was cooled and filtered, and the reaction solution was dried under reduced pressure, then extracted with DCM (10 mL) 3 times, and the organic phase was washed three times with water (10 mL) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the organic phase liquid was dried under reduced pressure, and the crude product was purified by silica gel column chromatography (DCM: MeOH = 10: 1) to obtain a black solid. A small amount of anhydrous THF was used to dissolve, and a white solid 7-1 (20 mg) was obtained by pre-HPLC.
[0330] LCMS: [M+H]+ =845.5.
[0331] Step b
[0332] At room temperature, 7-1 (20 mg, 0.023 mmol) was added to a 25 ml single-mouth bottle, DCM (2 mL) was added to dissolve, and then TFA (1 mL) was added and stirred at 25 degrees Celsius for 1 hour. LCMS showed that the product was detected. The reaction solution was then rotary concentrated under reduced pressure, and the crude product was dissolved in anhydrous THF, and the white solid Example 7 (10 mg) was obtained by pre-HPLC (using formic acid method).
[0333] LCMS: [M+H] + =645.3.
[0334] H-NMR: 1HNMR (400MHz, MeOD) δ9.09(d,J=7.7Hz,1H),7.42(dd,J=8.3,5.1Hz,1H),7.07(t,J=8.9Hz,1H),4.75(s,2H),4.53(s,2H),4.17(d,J=8 .2Hz,4H),4.13(s,2H),3.92(d,J=13.7Hz,2H),3.83(d,J=12.3Hz,2H), 3.18(s,2H),2.22(s,4H),2.15–2.02(m,4H),0.95(s,2H),0.86(s,2H).
[0335] Example 8
[0336]
[0337] Step a
[0338] Under room temperature, intermediate 9-6 (500 mg, 1.17 mmol) was dissolved in tetrahydrofuran (20 mL), and then compound 8-1 (506 mg, 1.25 mmol) and Cs2CO3 (1.14 g, 3.5 mmol) were added. Stir at 70 ° C for 17 hours. After the reaction was complete, water (100 mL) was slowly added and extracted three times with ethyl acetate (50 mL). The organic phase was dried over anhydrous sodium sulfate, and the organic phase liquid was concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column (PE: EA = 1: 3) to obtain a yellow solid 8-2 (157 mg).
[0339] LCMS: [M+H] + =565.4.
[0340] Step b
[0341] Under nitrogen protection, Preparation Example 7 (83 mg, 0.205 mmol), cesium carbonate (134 mg, 0.411 mmol) and DPEpHosPdCl2 (39 mg, 0.054 mmol) were added to a DMF (4 mL) solution of compound 8-2 (77 mg, 0.137 mmol). The mixture was stirred at 120 ° C. under microwave for 1 hour. LCMS showed that the reaction was complete, and the mixture was filtered after cooling and concentrated under reduced pressure to obtain a crude product, which was purified by Pre-HPLC (using formic acid method) to obtain a white solid 8-3 (30 mg).
[0342] LCMS: [M+H] + =821.6.
[0343] Step c
[0344] To a solution of intermediate 8-3 (25 mg, 0.03 mmol) in dichloromethane (1.0 mL) was added TFA (0.2 mL) and the mixture was stirred at 25 °C for 2 hours. LCMS showed that the product was detected. The reaction solution was then concentrated to give a crude product and was subjected to pre-HPLC (using formic acid method) to give Example 8 (10.43 mg) as a white solid.
[0345] LCMS: [M+H] + =621.2.
[0346] 1 H NMR (400MHz, CD3OD) δ9.11(s,1H),7.43(dd,J=8.3,5.2Hz,1H),7.07(t,J=8.9Hz,1H),5.48(d,J=53.1Hz,1H),4.82(s,2H),4.50(d,J=1 4.5Hz,2H),4.25(s,3H),3.95(d,J=13.9Hz,3H),3.53(d,J=40.6Hz,2H),3.14(s,2H),2.69–2.00(m,6H),0.94(dd,J=23.0,11.6Hz,4H).
[0347] Example 9
[0348]
[0349] The preparation of Example 9 can be prepared by a similar method to Example 8.
[0350] Example 9 was prepared from intermediate 9-3 (13.0 mg) by reaction of trifluoroacetic acid in dichloromethane to give a crude product and obtained by pre-HPLC (using formic acid method) as a white solid Example 9 (2.08 mg).
[0351] LCMS: [M+H] + =621.3.
[0352] 1 H NMR (400MHz, CD3OD) δ9.11(s,1H),7.43(dd,J=8.4,5.1Hz,1H),7.15–7.01(m,1H),5.61–5.35(m,1H),4.82(s,2H),4.50(dd,J=24.0 ,12.1Hz,2H),4.24(s,3H),3.94(d,J=13.9Hz,3H),3.62–3.46(m,2H),3.13(d,J=1.6Hz,2H),2.55–2.01(m,6H),1.04–0.83(m,4H).
[0353] Example 10
[0354]
[0355] The preparation of Example 10 can be prepared by a similar method to Example 8.
[0356] Example 10 was prepared from intermediate 10-3 (20.0 mg) by reaction of trifluoroacetic acid in dichloromethane to give a crude product and obtained as a white solid Example 10 (6.02 mg) by pre-HPLC (method of formic acid).
[0357] LCMS: [M+H] + =603.2.
[0358] 1 H NMR(400MHz,MeOD)δ9.14(s,1H),7.46(dd,J=8.0,5.2Hz,1H),7.10(t,J=8.9Hz,1H),4.84–4.79(m,2H),4.52(s,2H ),4.28(s,2H),4.04–3.83(m,4H),3.40(s,2H),3.21(s,2H),2.13(dd,J=23.8,9.9Hz,8H),0.95(d,J=27.9Hz,4H).
[0359] Embodiment 11
[0360]
[0361] The preparation of Example 11 can be prepared by referring to the similar method of Example 8, using borate (tert-butyl (3-cyano-4- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl) -5,7-difluorobenzo [b] thiophen-2-yl) carbamate (Preparation Example 7') instead of tert-butyl (3-cyano-4- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl) -7-fluorobenzo [b] thiophen-2-yl) carbamate (Preparation Example 7). The carbon-carbon coupling intermediate (35.0 mg) was reacted with a dichloromethane solution of trifluoroacetic acid to obtain a crude product and obtained by pre-HPLC (using formic acid method) as a white solid Example 11 (13.2 mg).
[0362] LCMS: [M+H] + =639.0.
[0363] 1H-NMR(DMSO-d6)d 9.12(1H,s),8.35(2H,s),7.35(1H,m),5.15-5.35(1H,dt),4.51(1H,m),4.13-4.41(3H,m),3.70(1H,d),3.55(3H,s )3.13-3.26(4H,m),2.78(2H,m),2.35(2H,m),1.76-2.09(2H,m),1.56(2H,t)1.01(1H,m),0.61(2H,t),0.41(2H,t).
[0364] Example 12
[0365]
[0366] The preparation of Example 12 can be prepared by referring to the similar method of Example 8, but using borate (tert-butyl (3-cyano-4- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl) -6,7-difluorobenzo [b] thiophen-2-yl) carbamate) instead of tert-butyl (3-cyano-4- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl) -7-fluorobenzo [b] thiophen-2-yl) carbamate (Preparation Example 7). The carbon-carbon coupling intermediate (15.0 mg) was reacted with a dichloromethane solution of trifluoroacetic acid to obtain a crude product and obtained by pre-HPLC (using formic acid method) as a white solid Example 12 (1.8 mg).
[0367] LCMS: [M+H] + =625.0.
[0368] Embodiment 13
[0369]
[0370] Step a
[0371] Under nitrogen protection, Preparation Example 7 (52 mg, 0.128 mmol), cesium carbonate (63 mg, 0.192 mmol) and DPEpHosPdCl2 (18 mg, 0.0256 mmol) were added to a solution of Preparation Example 11 (30 mg, 0.064 mmol) in N,N-dimethylformamide (1.5 mL) under nitrogen protection. The mixture was stirred under microwave at 120 ° C for 1 hour. LCMS showed that the reaction was complete, and the reaction solution was cooled and filtered. The filtrate was dried under reduced pressure to obtain a crude product, and the crude product was obtained by Pre-TLC and pre-HPLC (using formic acid method) to obtain a white solid 13-1 (11.0 mg).
[0372] LCMS: [M+H] + =723.3.
[0373] Step b
[0374] To a solution of intermediate 13-1 (20.0 mg, 0.028 mmol) in dichloromethane (1.0 mL) was added TFA (0.2 mL), and the mixture was stirred at 25 ° C for 1 hour. LCMS showed that the product was detected. The reaction solution was then concentrated under reduced pressure to obtain a crude product and pre-HPLC (using formic acid method) to obtain Example 13 (3.7 mg) as a white solid.
[0375] LCMS: [M+H]+ =623.3.
[0376] 1 H NMR (400MHz, CD3OD) δ9.28(s,1H),7.41(s,1H),7.07(t,J=8.8Hz,1H),5.52(d,J=52.0Hz,1H),4.67(d,J=9.7Hz,2H),4.57(s,1H),4.26(d,J=4.6Hz ,2H),3.78(d,J=17.9Hz,3H),3.48(s,1H),2.84(s,6H),2.63–2.50(m,2H) ,2.39(d,J=11.5Hz,4H),2.29(s,2H),2.11(s,1H),1.99(d,J=9.2Hz,2H).
[0377] Embodiment 14
[0378]
[0379] The preparation of Example 14 can be prepared by a similar method to Example 12 to obtain a white solid Example 14 (8.0 mg).
[0380] LCMS: [M+H] + =639.0.
[0381] Embodiment 15
[0382]
[0383] The preparation of Example 15 can be prepared by a similar method to Example 12 to obtain a white solid Example 15 (8.0 mg).
[0384] LCMS: [M+H] + =637.0.
[0385] 1 H NMR(400MHz,CD3OD)δ9.13(s,1H),7.42(dd,1H),4.82(s,2H),4.53(s,2H),4.27(s,2H ),3.95(m,4H),3.72–3.62(m,2H),3.23(s,2H),2.20–2.14(m,4H),1.14(ddt,4H),0.92 -0.78(m,4H).
[0386] Example 16
[0387]
[0388] The preparation of Example 16 can refer to the similar method of Example 8, and replace tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,7-difluorobenzo[b]thiophen-2-yl)carbamate (Preparation Example 7) with borate tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-7-fluorobenzo[b]thiophen-2-yl)carbamate to obtain white solid Example 16 (16.5 mg).
[0389] LCMS: [M+H] + =625.0.
[0390] 1H-NMR(DMSO-d6)d 9.21(1H,s),8.33(2H,s),7.35(1H,m),5.25-5.45(1H,dt),4.51(2H,m),4.03-4.21(2H,m),3.85(2H,s),3. 70(2H,d),3.13-3.26(4H,m),3.05(1H,s),2.82(1H,m),2.15(1H,m),2.09(2H,s),1.72(2H,t)1.27(4H,t).
[0391] Embodiment 17
[0392]
[0393] The preparation of Example 17 can refer to the similar method of Example 8, and replace tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,7-difluorobenzo[b]thiophen-2-yl)carbamate (Preparation Example 7) with borate tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-7-fluorobenzo[b]thiophen-2-yl)carbamate to obtain white solid Example 17 (16.5 mg).
[0394] LCMS: [M+H] + =637.0.
[0395] 1H-NMR(DMSO-d6)d 8.82(1H,s),8.01(2H,s),7.07(1H,m),4.35(1H,m),4.06(5H,m),3.43-3. 07(6H,m),2.03-2.26(6H,m),1.26-1.42(5H,m),0.43(2H,t),0.21(2H,t).
[0396] Embodiment 18
[0397]
[0398] The preparation of Example 18 can refer to the similar method of Example 8, and replace tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,7-difluorobenzo[b]thiophen-2-yl)carbamate (Preparation Example 7) with borate (tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-7-fluorobenzo[b]thiophen-2-yl)carbamate to obtain white solid Example 18 (22.0 mg).
[0399] LCMS: [M+H] + =663.0.
[0400] Embodiment 19
[0401]
[0402] The preparation of Example 19 can refer to the similar method of Example 8, and replace tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,7-difluorobenzo[b]thiophen-2-yl)carbamate (Preparation Example 7) with borate (tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-7-fluorobenzo[b]thiophen-2-yl)carbamate to obtain white solid Example 19 (12.0 mg).
[0403] LCMS: [M+H]+=649.0.
[0404] Embodiment 20
[0405]
[0406] The preparation of Example 20 can be prepared by a similar method to Example 19 to obtain a white solid Example 20 (6.7 mg).
[0407] LCMS: [M+H]+=649.0.
[0408] Embodiment 21
[0409]
[0410] The preparation of Example 21 can refer to the similar method of Example 8, and replace tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,7-difluorobenzo[b]thiophen-2-yl)carbamate (Preparation Example 7) with borate (tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-7-fluorobenzo[b]thiophen-2-yl)carbamate to obtain white solid Example 21 (25.0 mg).
[0411] LCMS: [M+H]+=661.0.
[0412] Embodiment 22
[0413]
[0414] Step a
[0415] Under argon protection at room temperature, to a solution of Preparation Example 10 (250 mg, 0.536 mmol) in N, N-dimethylformamide (15 mL) were added Preparation Example 7' (340 mg, 0.805 mmol), DPEpHosPdCl2 (192 mg, 0.268 mmol), cuprous chloride (105 mg, 1.072 mmol) and cesium carbonate (697 mg, 2.144 mmol). The resulting mixture was stirred for 4 hours under argon protection at 110 ° C. The reaction was complete as detected by LCMS. The reaction solution was filtered, eluted with ethyl acetate three times, and the filtrate was collected and vacuum evaporated. The crude product after spin drying was purified by reverse phase C18 silica gel column chromatography (10 mmol NH4HCO3 aqueous solution in 35% to 100% acetonitrile solution, 85% acetonitrile, 20 minutes, 254 nm monitoring) to obtain 22-1 (35 mg, 8.8%) as an off-white solid.
[0416] LCMS: [M+H]+ =741
[0417] Step b
[0418] Trifluoroacetic acid (2 mL) was added to a solution of compound 22-1 (35 mg, 0.047 mmol) in dichloromethane (8 mL) under an ice-water bath. The reaction solution was stirred for 3 hours under an ice-water bath. LCMS showed that the reaction was complete and the reaction solution was concentrated in vacuo. The crude product after spin drying was purified by reverse phase C18 silica gel column chromatography (10 mmol / L NH4HCO3 aqueous solution in 25% to 95% methanol solution, 25 minutes, 254 / 220 nm monitoring) to obtain Example 22 (3 mg, 10%) as a white solid.
[0419] LCMS: [M+H] + =640
[0420] 1H NMR(300MHz,DMSO-d6)δ9.41(s,1H),8.86(s,1H),8.24(s,2H),7.69(dt,J=13.3,5.0Hz,1H),7.28(t,J=9.9Hz,1H),5.40-5.21(m,1H),4.28– 4.11(m,3H),3.86(d,J=14.9Hz,1H),3.05(s,1H),2.86(s,1H),2.33(s ,6H),2.06(s,5H),1.82(s,6H),1.24-1.20(m,1H),0.97–0.81(m,1H).
[0421] Embodiment 23
[0422]
[0423] Step a
[0424] At 0°C, sodium thiomethoxide (196 mg, 2.8 mmol) was added to a DMF (15 mL) solution of compound 9-6 (1 g, 2.33 mmol). The reaction solution was stirred at room temperature for 1 hour. After the reaction was completed by LCMS, 60 mL of saturated brine was added to the reaction solution, and 40 mL of ethyl acetate was extracted three times. The organic phases were combined, dried and filtered, and the crude product after the organic phase was dried was purified by silica gel (PE / EA=3:1) to obtain compound 23-2 (600 mg, 63.7%) as a white solid.
[0425] LCMS: [M+H]+=440
[0426] Step b
[0427] Add 23-2 (500 mg, 1.14 mmol), Preparation Example 7 boric acid ester (573 mg, 1.7 mmol), DPEphosPdCl2 (326 mg, 0.46 mmol), Cs2CO3 (1.48 g, 4.55 mmol) and ultra-dry DMF (15 mL) into the bottle and stir at 75 ° C for 5 hours under N2 protection. TLC monitors the reaction and the conversion of raw materials is complete. Pour the reaction solution into (80 mL) saturated brine, extract 3 times with 40 mL of ethyl acetate, collect the organic phase, vacuum evaporate the organic phase, and purify the crude product after spin drying by silica gel (PE / EA = 0-30%) to obtain compound 23-3 (150 mg, 19%) as a light yellow solid.
[0428] LCMS: [M+H] + =696
[0429] Step c
[0430] At room temperature, m-CPBA (75 mg, 0.431 mmol) was added to a solution of 23-3 (150 mg, 0.216 mmol) in dichloromethane (20 mL). The reaction was stirred at room temperature for 30 minutes, and the conversion of the raw material was monitored by TLC. The reaction solution was evaporated to dryness in vacuo to obtain a crude product, which was purified by silica gel (PE / EA = 0-40%) to obtain an off-white solid 23-4 (100 mg, 63.7%).
[0431] LCMS: [M+H] + =728
[0432] Step d
[0433] At 0°C, t-BuONa (12 mg, 0.13 mmol) was added to a solution of 23-5 (21 mg, 0.13 mmol) and 4A molecular sieve in ultra-dry tetrahydrofuran (4 mL), stirred for 30 minutes, and then 23-4 (30 mg, 0.04 mmol) in ultra-dry tetrahydrofuran (2 mL) was added dropwise to the previous solution. After TLC detection of the conversion of the raw material was completed, the reaction solution was spin-dried and the crude product was purified by Prep-TLC (DCM / MeOH=30:1) to give 23-6 (17 mg, 50%) as a light yellow solid.
[0434] LCMS: [M+H] + =819
[0435] Step e
[0436] Trifluoroacetic acid (1 mL) was added to a solution of 23-6 (27 mg, 0.0528 mmol) in dichloromethane (4 mL) at room temperature. The reaction mixture was stirred at room temperature for 2 hours. LCMS showed that the reaction was complete, and the reaction mixture was concentrated in vacuo to give a brown-yellow oil. The crude product was purified by Prep-TLC using DCM / MeOH (0.5% ammonia water) as the developing solvent to give 9 mg of Example 23 as a white solid.
[0437] LCMS: [M+H] + =619
[0438] 1H NMR (300MHz, CD3OD) δ9.09(s,1H),7.44(dd,J=8.4,5.1Hz,1H),7.09(dd,J=9.4,8.4Hz,1H),4.81(d,J=13.8Hz,2H),4.49(s,2H),4.27 –4.14(m,2H),3.92(d,J=13.7Hz,2H),3.80–3.74(m,2H),2.94–2.69(m,4H),2.10(m,4H),1.19–1.10(m,4H),0.83(m,2H),0.66(m,2H).
[0439] Embodiment 24
[0440]
[0441] The preparation of Example 24 can refer to the similar method of Example 8, and use borate tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,7-difluorobenzo[b]thiophen-2-yl)carbamate (Preparation Example 7') to replace tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-7-fluorobenzo[b]thiophen-2-yl)carbamate (Preparation Example 7) to prepare white solid Example 24 (24 mg).
[0442] LCMS: [M+H] + =665
[0443] 1H NMR (300MHz, DMSO-d6) δ9.07(s,1H),8.24(s,2H),7.29(t,J=9.9Hz,1H),4.48(s,2H),4.31(s,2H),3.91–3.79(m,2H),3.69(s,1H ),3.54(s,3H),2.45–2.35(m,3H),2.18–2.03(m,4H),1.61(s,3H),1.45(s,1H),1.08(d,J=6.4Hz,6H),0.65(s,2H),0.40(s,2H).
[0444] Embodiment 25
[0445]
[0446] The preparation of Example 25 can refer to the similar method of Example 8, and replace tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,7-difluorobenzo[b]thiophen-2-yl)carbamate (Preparation Example 7') with borate tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-7-fluorobenzo[b]thiophen-2-yl)carbamate to obtain white solid Example 24 (2.9 mg).
[0447] LCMS: [M+H] + =665
[0448] Embodiment 26
[0449]
[0450] Step a
[0451] At room temperature, DIEA (0.906 g, 7.026 mmol), compound 1,1-cyclopropane dimethanol (2.15 g, 21.08 mmol) and cesium carbonate (6.85 g, 21.08 mmol) were added to a mixed solvent of tetrahydrofuran (25 mL) and N,N-dimethylformamide (25 mL) of 9-6 (3.0 g, 7.03 mmol) at room temperature. The resulting mixture was stirred at room temperature for 6 hours. The reaction was completed by LCMS. The reaction solution was quenched with ice water, extracted with ethyl acetate, the organic phases were combined and washed with saturated sodium chloride solution, the organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was collected and vacuum evaporated, and the crude product after spin drying was purified by normal phase silica gel column chromatography (DCM / MeOH=10:1) to obtain 26-2 (2.5 g, 72.2%) as an off-white solid.
[0452] LCMS: [M+H] + =494
[0453] Step b
[0454] Under argon protection at room temperature, to a DMF (15 mL) solution of 26-2 (200 mg, 0.41 mmol) was added a difluoroborate (257 mg, 0.61 mmol), DPEpHosPdCl2 (116 mg, 0.16 mmol), cuprous chloride (80 mg, 0.81 mmol) and cesium carbonate (527 mg, 1.62 mmol) similar to those in Preparation Example 7. The resulting mixture was stirred at 120 ° C under argon protection for 3 hours. The reaction was completed by LCMS. The reaction solution was quenched with ice water, filtered, eluted with ethyl acetate, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, collected by filtration and vacuum evaporated. The crude product after spin drying was purified by normal phase silica gel column chromatography (PE / EA=1:1) to obtain 26-3 (119 mg, 41.5%) as a light yellow solid.
[0455] LCMS: [M+H] + =768
[0456] Step c
[0457] At room temperature, Dess-Martin oxidant (99 mg, 0.233 mmol) was added to a solution of 26-3 (119 mg, 0.155 mmol) in dichloromethane (10 mL). The resulting mixture was stirred for 2 hours under argon protection at room temperature. The reaction was complete as determined by LCMS. The reaction solution was quenched with saturated aqueous sodium bicarbonate solution, extracted with dichloromethane, the organic phases were combined and washed with saturated brine, the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was vacuum evaporated. The crude product after spin drying was purified by normal phase silica gel column chromatography (PE / EA=1:1) to obtain 26-4 (93 mg, 78.5%) as a light yellow solid.
[0458] LCMS: [M+H] + =766
[0459] Step d
[0460] Under argon protection at room temperature, compound 3-fluoro-3-methylpyrrolidine hydrochloride (34 mg, 0.24 mmol) was added to a solution of 26-4 (93 mg, 0.12 mmol) in 1,2-dichloroethane (10 mL). The resulting mixture was stirred for 16 hours under argon protection at room temperature. Then sodium triacetoxyborohydride (38 mg, 0.18 mmol) and 1 drop of glacial acetic acid were added to the above reaction solution and stirred for 3 hours under argon protection at room temperature. The reaction was completed by LCMS detection. Under an ice-water bath, the reaction was quenched with a saturated aqueous sodium bicarbonate solution, stirred for 30 minutes, extracted with dichloromethane, the organic phases were combined and washed with a saturated sodium chloride solution, the organic phases were dried over anhydrous sodium sulfate, filtered, the filtrate was collected and vacuum evaporated. The crude product was dried and purified by reverse phase C18 silica gel column chromatography (10 mM NH4HCO3 aqueous solution in 40% to 100% methanol solution, 30 minutes, monitoring at 254 / 220 nm) to give 26-5 (70 mg, 68%) as an off-white solid.
[0461] LCMS: [M+H] + =853
[0462] Step e
[0463] Trifluoroacetic acid (2 mL) was added to a solution of 26-5 (70 mg, 0.082 mmol) in dichloromethane (8 mL) at room temperature. The reaction mixture was stirred at room temperature for 6 hours. LCMS showed that the reaction was complete and the reaction mixture was concentrated in vacuo. The crude product after spin drying was purified by reverse phase C18 silica gel column chromatography (10 mM NH4HCO3 aqueous solution in 40% to 100% methanol solution, 254 / 220 nm monitoring) to obtain Example 26 (20 mg, 37.3%) as an off-white solid.
[0464] LCMS: [M+H] + =653
[0465] 1H NMR(300MHz,DMSO-d6)δ9.09(s,1H),8.23(s,2H),7.29(t,J=9.9Hz,1H),4.51(d,J=12.2Hz, 1H),4.34(d,J=10.8Hz,2H),4.24(d,J=10.8Hz,1H),3.68(s,1H),3.55(s,3H),2.92–2.69(m ,2H),2.46(d,J=10.0Hz,2H),2.38(d,J=12.7Hz,1H),2.09–1.80(m,1H),1.76(s,1H),1.63( s,3H),1.45(s,2H),1.38(s,2H),1.24(s,1H),0.64(d,J=5.5Hz,2H),0.44(d,J=4.6Hz,2H).
[0466] Embodiment 27
[0467]
[0468] The preparation of Example 27 can refer to the similar method of Example 26 using 1-fluoro-3-azabicyclo[3.1.0]hexane chiral separation of the latter peak to prepare white solid Example 27 (7 mg).
[0469] LCMS: [M+H] + =651
[0470] Embodiment 28
[0471]
[0472] The preparation of Example 28 can be carried out by referring to a similar method to Example 8, using borate tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,7-difluorobenzo[b]thiophen-2-yl)carbamate (Preparation Example 7') to replace tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-7-fluorobenzo[b]thiophen-2-yl)carbamate (Preparation Example 7) to obtain white solid Example 28 (12 mg).
[0473] LCMS: [M+H] + =665
[0474] Embodiment 29
[0475]
[0476] The preparation of Example 29 can refer to the similar method of Example 26 and use tert-butyl (3-cyano-4- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl) -7-fluorobenzo [b] thiophen-2-yl) carbamate (Preparation Example 7) to prepare white solid Example 29 (50 mg).
[0477] LCMS: [M+H] + =639
[0478] Test Example 1: KRAS G12D protein competitive inhibition activity experiment (Competition assay)
[0479] This experiment uses homogeneous time-resolved fluorescence (HTRF) to identify a class of compounds that compete for binding to the GDP form of KRAS protein and that can compete to displace the fluorescently labeled probe occupying the KRAS protein binding site. Biotinylated recombinant KRAS protein (sequence 1-188AA) was purified and expressed in E. coli, and the target compound was diluted in a gradient ratio using DMSO solution to obtain a series of compound concentrations. During the experiment, 5nM KRAS G12D, 25nM fluorescently labeled probe and target compound diluted in reaction buffer (50mM HEPES pH 7.5, 5mM MgCl2, 1mM DTT) were added to a 384-well white shallow well plate (PerkinElmer), and appropriate control wells were set up. GDP-KRAS protein, fluorescently labeled probe and compound were pre-incubated in a 384-well plate for 30 minutes, and then diluted 0.5nM Tb-SA (Cisbio) was added to start the reaction. After sealing the plate and incubating at room temperature in the dark for 1 hour, the TR-FRET signal value (excitation wavelength: 320 nm, emission wavelength: 615 nm and 665 nm) was measured using EnVision microplate reader (PerkinElmer). Calculate the fluorescence signal ratio RLU = (665 nm signal / 615 nm signal) x 104; the % inhibition rate of the competitive binding between the target compound and the labeled probe at different concentrations was calculated by setting the 0% inhibition rate and 100% inhibition rate signal wells.
[0480] Compound inhibition rate IR (%) formula = (RLU0% inhibition-RLU compound) / (RLU0% inhibition-RLU100% inhibition) x 100%, using the four-parameter logistic model to fit the compound gradient dilution concentration and the corresponding inhibition rate, and calculate the IC50 value. The competitive inhibition activity (IC50, μM) of the test compound on KRAS G12D protein is shown in Table 1 below.
[0481] Test Example 2: KRAS protein interaction (PPI) experiment
[0482] In this experiment, the homogeneous time-resolved fluorescence (HTRF) method was used to detect the inhibitory activity of small molecule compounds on the interaction between KRAS protein and downstream RAF1 protein in the GTP-activated state. The purified Tag1-RAF1 protein stock solution was diluted 100 times with TR-FRET buffer. Similarly, the purified Tag2-KRAS protein and GTP mixture were diluted 100 times with buffer to ensure that the final concentration of GTP was 10μM. The working concentrations of these proteins were optimized to ensure the generation of maximum signals. The test compounds were graded and diluted with DMSO solution to obtain a series of compound concentrations, and the final concentration of DMSO was controlled to be 0.5%. 4μL GTP-KRAS protein, 4μL RAF1 protein and 2μL compound working solution were added to a 384-well white shallow well plate (PerkinElmer), and appropriate control wells were set simultaneously. GTP-KRAS protein, RAF1 protein and compound were pre-incubated in a 384-well plate for 15 minutes, and then 10μL Anti-Tag1-Eu diluted in HTRF detection buffer was added. 3+ The reaction was initiated by adding a mixture of anti-Tag2-XL665 labeled antibodies. The plates were sealed and incubated at 4°C in the dark for 2 hours. The TR-FRET signal value was measured using an EnVision microplate reader (PerkinElmer) (excitation wavelength: 320 nm, emission wavelength: 615 nm and 665 nm). The fluorescence signal ratio RLU was calculated as (665 nm signal / 615 nm signal) x 10 4 The compound % inhibition rate is calculated by setting the 0% inhibition rate well and the 100% inhibition rate well signals.
[0483] Compound inhibition rate IR (%) formula = (RLU 0%抑制 -RLU 化合物 ) / (RLU 0%抑制 -RLU 100%抑制 ) x 100%, and the IC 50The inhibitory activity of the test compound on KRAS G12D protein (IC 50 , μM) results are shown in Table 1 below.
[0484] Test Example 3: KRAS GDP-GTP Nucleotide Exchange Assay
[0485] In this experiment, the homogeneous time-resolved fluorescence (HTRF) method was used to detect the inhibitory activity of small molecule compounds on the conversion of KRAS protein from the GDP-inactive state to the GTP-activated state. BODIPY-GDP loaded His-KRAS (G12D, aa2-186, BPS bioscience) or BODIPY-GDP loaded His-KRAS (WT, aa 2-185, BPS bioscience) and MAb Anti-6HIS Tb cryptate Gold (Cisbio) were mixed (final concentration: KRAS 100nM; Tb 0.335nM) and incubated at 25°C for 30min. Then, the target compound was diluted in a gradient ratio using DMSO solution to obtain a series of compound concentrations, and the final concentration of DMSO was controlled to be 1%. 5μL of the mixture of GDP-KRAS protein and Anti-6HIS Tb and 5μL of compound working solution were added to a 384-well white shallow well plate (PerkinElmer). The plate was sealed and incubated at 25°C in the dark for 1 hour. Then, 5 μL of SOS1 (Cytoskeleton) / GTP (Sigma) mixture (final concentration: SOS1 150 nM; GTP 10 μM) was added, and appropriate control wells were set. The plate was sealed, and the TR-FRET signal value (excitation wavelength: 320 nm, emission wavelength: 615 nm and 665 nm) was measured using EnVision microplate reader (PerkinElmer) after incubation at 25°C in the dark for 20 min. Calculate the fluorescence signal ratio RLU = (665 nm signal / 615 nm signal) x104; the % inhibition rate of the target compound inhibiting the nucleotide conversion of KRAS protein at different concentrations was calculated by setting the 0% inhibition rate and 100% inhibition rate signal wells.
[0486] Compound inhibition rate IR (%) formula = (RLU0% inhibition-RLU compound) / (RLU0% inhibition-RLU100% inhibition) x 100%, using the four-parameter logistic model to fit the compound gradient dilution concentration and the corresponding inhibition rate to calculate IC 50 The inhibitory activity (IC50, μM) of the test compounds on KRAS protein nucleotide turnover is shown in Table 1 below.
[0487] Example Activity Data
[0488] Table 1
[0489]
[0490]
[0491] Note: NA: not applicable.
[0492] It can be seen from the above results that when the SOS1-catalyzed KRAS-GDP G12D protein undergoes nucleotide exchange, the compounds of the present application exhibit higher selectivity relative to the wild type, and compared with the positive control compound KRpep-2d, both the activity and selectivity are greatly improved. It can also be seen from the above examples that, compared with the positive control compound, it is suggested that the compounds of the present invention not only have higher activity in inhibiting the protein-protein interaction of GTP-KRAS-RAF1, but also have higher activity and higher selectivity for the wild type in inhibiting the nucleotide exchange of the KRAS-GDP protein catalyzed by SOS1.
[0493] Test Example 4: Tumor Cell Line Proliferation Inhibition Experiment (2D)
[0494] Five tumor cell lines AGS (G12D), PANC-1 (G12D), GP2D (G12D), ASPC-1 (G12D) and BXPC-3 (WT) from commercial sources were selected for cell proliferation inhibition experiments. They were cultured in F12, DMEM, DMEM, RPMI-1640 and RPMI-1640 culture media (Gibco, ThermoFisher) containing 10% fetal bovine serum, respectively, and incubated in a 37°C, 5% CO2 incubator. The cells all grew in an adherent state, and the growth status was observed under an inverted microscope. When the number of cells was appropriate, they were subcultured.
[0495] Take five cell lines of AGS, PANC-1, GP2D, ASPC-1 and BXPC-3 in the logarithmic growth phase, inoculate them in a 96-well cell culture plate (Corning) at an appropriate cell density, and culture them at 37°C in a cell culture incubator containing 5% CO2 for 24 hours, and then add 10 μL of the test compound or positive drug to each well. At the same time, set up a positive control group (100% inhibition well) and a negative control group (0% inhibition well), repeat 2 wells for each concentration of the drug group, and repeat 6 wells for the positive control group and the negative control group. After continuing to culture in the incubator for 5 days, the subsequent AlamarBlue test operation is carried out.
[0496] AlamarBlue test operation: add 10 μL AlamarBlue reagent (ThermoFisher) to each well, incubate for 1-4h, shake for 1-2min, measure the fluorescence value with MD microplate reader EX: 560nm, EM: 590nm wavelength, record the results, calculate the drug inhibition rate on cells (%) = (A0% inhibition - A drug) / (A0% inhibition - A100% inhibition) × 100%, and then use MATILAB software to use nonlinear regression method (usually using four-parameter fitting curve equation, 4-parameter logistic model)) to draw the drug dose response curve, so as to obtain the IC of the compound 50 The proliferation inhibitory activity (IC) of the test compounds on five commercial tumor cell lines (AGS, PANC-1, GP2D, ASPC-1 and BXPC-3) was analyzed. 50 , μM) results are shown in Table 2 below.
[0497] Example Activity Data (Proliferation)
[0498] Table 2
[0499]
[0500]
[0501] Test Example 5 Determination of phosphorylated p-ERK1 / 2 (THR202 / TYR204) in AGS and PANC-1 cells
[0502] AGS (ECACC, 89090402) and PANC-1 (ATCC, CRL-1469) both contain KRAS G12D mutation. This method uses the Advanced phospho-ERK1 / 2 (Thr202 / Tyr204) kit (Cat. No. 64AERPEH) of CISBIO to determine the inhibitory activity of the compounds of the present invention on p-ERK1 / 2 protein in AGS and PANC-1 cells.
[0503] The experimental process is briefly described as follows: AGS cells and PANC-1 cells were cultured in HAMF12 medium and DMEM medium (Gibco) containing 10% FBS (Gibco), respectively. On the first day of the experiment, AGS cells and PANC-1 cells were seeded into 96-well cell culture plates at a density of 20,000 cells / well and placed in a cell culture incubator (37°C, 5% CO2) for overnight incubation. On the second day, the culture medium in the 96-well cell culture plate was removed, and 10 μL of fresh culture medium containing the compound to be tested in a gradient dilution was added, and then the cell culture plate was placed in a cell culture incubator (37°C, 5% CO2) for 2 hours. After 2 hours, the culture plate was removed, the culture medium in the 96-well cell culture plate was removed, 50 μL of 1× cell lysis solution (Cisbio) was added to each well, and the cell culture plate was placed in a microplate constant temperature incubator and incubated at 25°C for 45 minutes. After the cells are fully lysed, mix them by pipetting, then transfer 16 μL of cell lysate to a 384-well white plate (Corning), then pipette 4 μL / well of pre-mixed phospho-ERK1 / 2 antibody and add it to the 384-well plate containing the cell lysate, seal the plate and centrifuge to mix, then place the 384-well plate in a microplate thermostat incubator and incubate at 25°C for 4 hours. Finally, use EnVision microplate reader (PerkinElmer) to measure the TR-FRET signal value (excitation wavelength: 320 nm, emission wavelength: 615 nm and 665 nm). Calculate the fluorescence signal ratio RLU = (665 nm signal / 615 nm signal) x 10 4 The % inhibition rate of the compound of the present invention at different concentrations in inhibiting the intracellular p-ERK1 / 2 protein is calculated by setting the 0% inhibition rate and 100% inhibition rate signal wells.
[0504] Compound inhibition rate IR (%) formula = (RLU0% inhibition-RLU compound) / (RLU0% inhibition-RLU100% inhibition) x 100%, by calculating the compound concentration and the corresponding inhibition rate, fitting the standard curve (4-parameter logistic model), and calculating the IC50 value. The inhibitory activity (IC50, μM) of the compounds of the present invention on p-ERK1 / 2 protein in AGS and PANC-1 cells is shown in Table 3 below.
[0505] Table 3 Example p-ERK activity data
[0506] Example AGS PANC-1 8 0.359 0.022 11 0.067 0.008 16 0.097 0.009 17 0.017 0.029 18 0.137 0.046 19 0.871 0.263 21 0.229 0.069
[0507] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A compound represented by the following formula (IIA) or formula (IIB), or a pharmaceutically acceptable salt thereof: in, R 1 Selected from the following group: hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 cyanoalkyl, C1-C6 hydroxyalkyl, allyl, -C(=O)H, -CO2R 5 、-C(=O)R 6 、-SO2R 7 、-CO2N(R 5 )2, aryl, heteroaryl, CONH2, CONR a R b or CONHR c ; where R a , R b , R c are respectively selected from: C1-C6 alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl; Q is a bond, S, O or NR 5 ; R 2 Selected from the group consisting of hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl; R 3 Selected from the group consisting of H, D, halogen, OH, OR, CH2OH, CH2OR, CN, NH2, NHR, N(R)2, or Wherein, R is C1-C4 alkyl, C1-C4 alkoxy; R 4 is hydrogen, -N(R 5 )2, heterocyclic group, C1-C6 alkyl group, -M-heterocyclic group, -M-aryl group, -M-heteroaryl group, -M-cycloalkyl group, -MN(R 5 )2, -M-NHC(=NH)NH2, -MC(=O)N(R 5 )2, -M-C1-C6 haloalkyl, -M-OR 5 、-M-(CH2OR 5 )(CH2) n OR 5 、-M-NR 5 C(O)-aryl, -M-COOH or -MC(=O)O(C1-C6 alkyl), wherein each heterocyclyl, aryl, cycloalkyl or heteroaryl moiety may be optionally replaced by one or more R 6 wherein the aryl or heteroaryl of -M-aryl and -M-heteroaryl may be optionally substituted by one or more R 7 replace; Each M is independently a chemical bond, a C1-C6 alkylene group, or a C2-C6 alkenylene group; wherein the M may be optionally substituted by one or more substituents selected from the group consisting of a hydroxyl group, an amine group, a C1-C4 hydroxyalkyl group, or a heteroaryl group; Each R 5 Each is independently hydrogen, C1-C6 alkyl or C1-C6 haloalkyl; or R 4 and R 5 and the N atoms connected thereto together form a 4-7 membered saturated nitrogen heterocyclic ring; wherein the 4-7 membered saturated nitrogen heterocyclic ring may be optionally replaced by one or more R 6 replace; Each R 6 Each is independently halogen, hydroxyl, C1-C6 hydroxyalkyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, cyano, heterocyclic, -L-phenyl, -L-phenylSO2F, -C(=O)NH2, -NHC(=O)phenyl, -NHC(=O)phenylSO2F, heteroaryl, arylC1-C6alkyl-, tert-butyldimethylsiloxyCH2-, -N(R 5 )2, (C1-C6 alkoxy) C1-C6 alkyl-, (C1-C6 alkyl) C(=O), oxo, (C1-C6 haloalkyl) C(=O)-, -SO2F, (C1-C6 alkoxy) C1-C6 alkoxy, -CH2OC(=O)N(R 5 )2, -CH2NHC(=O)OC1-C6alkyl, -CH2NHC(=O)N(R 5 )2, -CH2NHC(=O)C1-C6 alkyl, -CH2(heteroaryl), -CH2heterocyclyl, -CH2NHSO2C1-C6 alkyl, -CH2OC(=O)heterocyclyl, -OC(=O)N(R 5 )2, -OC(=O)NH(C1-C6 alkyl)O(C1-C6 alkyl), -OC(=O)NH(C1-C6 alkyl)O(C1-C6 alkyl)phenyl(C1-C6 alkyl)N(CH3)2, -OC(=O)NH(C1-C6 alkyl)O(C1-C6 alkyl)O(C1-C6 alkyl)alkyl)phenyl or -OC(=O)heterocyclyl; wherein the phenyl group of -NHC(=O)phenyl or -OC(=O)NH(C1-C6 alkyl)O(C1-C6 alkyl)phenyl is optionally substituted by -C(=O)H or OH, and the heterocyclyl group in the -CH2heterocyclyl group may also be optionally substituted by oxo; Wherein, L is a chemical bond or O; Each R 7 Each is independently selected from the following group: halogen, hydroxyl, HC(=O)-, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 hydroxyalkyl or -N(R 5 )2; X is selected from the group consisting of halogen, hydroxyl, mercapto, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkanethio; Y is selected from the group consisting of H, halogen, hydroxy, mercapto, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkanethio; Z is selected from the group consisting of H, halogen, hydroxyl, mercapto, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkanethio; R9 is selected from the group consisting of H, halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 deuterated alkyl, C1-C4 haloalkoxy, C2-C4 alkenyl, C3-C6 cycloalkyl; R 10 Selected from the group consisting of H, halogen, cyano, hydroxy, nitro, amino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 deuterated alkyl, C1-C4 haloalkoxy, C2-C4 alkenyl, C3-C6 cycloalkyl; R 13 Selected from the group consisting of H, halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 deuterated alkyl, C1-C4 haloalkoxy, C2-C4 alkenyl, C3-C6 cycloalkyl; R 14 Selected from the group consisting of H, halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 deuterated alkyl, C1-C4 haloalkoxy, C2-C4 alkenyl, C3-C6 cycloalkyl; R 15 Selected from the group consisting of H, methyl, ethyl, acetyl, tert-butoxycarbonyl, deuterated methyl, deuterated ethyl, ethoxycarbonyl; Each R'1 is independently selected from the group consisting of H, methyl, ethyl, C3-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 cycloalkoxy, C1-C6 cycloalkanethiol, deuterated methyl, deuterated ethyl; Wherein, the aryl group is C6-C 14 The aryl group and the heterocyclic group are 3-12 membered heterocyclic groups, the heteroaryl group is 5-14 membered heteroaryl group (e.g., 5-6 membered heteroaryl group or benzo 5-6 membered heteroaryl group), and the cycloalkyl group is C3-C 12 and unless otherwise specified, the aryl, heteroaryl and cycloalkyl groups may optionally have 1 to 3 substituents selected from the group consisting of halogen, C1-C6 alkyl.
2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, characterized in that The compound has a structure shown in the following formula (I) or formula (II): Wherein, each R'1 is independently selected from the following group: H, methyl, ethyl, C3-C6 alkyl, C3-C6 haloalkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylthiol, C1-C6 cycloalkyloxy, C1-C6 cycloalkylthiol, deuterated methyl, deuterated ethyl; the definitions of the remaining groups are as described in claim 1.
3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, characterized in that The compound has a structure shown in the following formula:
4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, characterized in that The compound has a structure shown in the following formula: Among them, the R 11 is selected from the group consisting of H, deuterium, halogen, methyl, hydroxymethyl, ethyl, C3-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 cycloalkoxy, C1-C6 cycloalkanethiol, deuterated methyl, deuterated ethyl, halomethyl, halomethoxy; or two R 11 The carbon atoms connected thereto together form a 3-9-membered cycloalkyl or heterocyclic group; m is 0, 1, 2, 3 or 4.
5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, characterized in that The compound has a structure shown in the following formula: Among them, the R 11 is selected from the group consisting of H, deuterium, halogen, methyl, ethyl, C3-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 cycloalkoxy, C1-C6 cycloalkanethiol, deuterated methyl, deuterated ethyl, halomethyl, halomethoxy; or two R 11 The carbon atoms connected thereto together form a 3-10 membered cycloalkyl or heterocyclic group; m is 0, 1, 2, 3 or 4.
6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, characterized in that The compound has a structure shown in the following formula: Among them, the R 11 Selected from the group consisting of H, deuterium, halogen, methyl, ethyl, C3-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 cycloalkoxy, C1-C6 cycloalkanethiol, deuterated methyl, deuterated ethyl, halomethyl, halomethoxy; m is 0, 1, 2, 3, 4, 5 or 6.
7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein The compounds have the structures shown in the following table:
8. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein The R 4 having a structure selected from the group consisting of: -M-heterocyclyl, -M-aryl, -M-heteroaryl, -M-cycloalkyl; wherein each heterocyclyl, aryl, cycloalkyl or heteroaryl moiety may be optionally replaced by one or more R 6 wherein the aryl or heteroaryl of -M-aryl and -M-heteroaryl may be optionally substituted by one or more R 7 replace; Wherein, the aryl group is C6-C 10 The aryl and heterocyclic groups are 4-6-membered monocyclic heterocyclic groups or 7-9-membered cyclic heterocyclic groups, the heteroaryl groups are 5-6-membered monocyclic heteroaryl groups or 9-10-membered cyclic heterocyclic groups, and the cycloalkyl groups are C3-C6 monocyclic alkyl groups or C7-C 10 Cycloalkyl; Each R 6 Each is independently halogen, hydroxyl, C1-C6 hydroxyalkyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, cyano, heterocyclic, C1-C6 alkyl-substituted heteroaryl, aryl C1-C6 alkyl-, -N(R 5 )2, (C1-C6 alkoxy)C1-C6 alkyl-, (C1-C6 alkyl)C(=O), -C(=O)NH2, -CH2(heteroaryl), -CH2heterocyclyl; Each R 7 Each is independently selected from the following group: halogen, hydroxyl, HC(=O)-, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 hydroxyalkyl or -N(R 5 )2.
9. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein The R 4 Having a structure selected from the group consisting of: Preferably, when R 4 When it is the above groups, Q is O, S, NH, CO; Preferably, when R 4 When it is the above-mentioned group, Q is a single bond.
10. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, characterized in that The Selected from the group consisting of CHF2, CH2F, CF3, CF2Cl, CF2CH3.
11. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, characterized in that The compound has the structure shown below: Among them, in formula IA, IB, IC, (R 1_1 ) n is selected from D, halogen, OH, C1-C4 alkyl, C1-C4 deuterated alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, CH2OH, CH2CH2OH, CH2(C1-C4 alkoxy, CN, NH2); the remaining groups are as defined in claim 1; In the remaining formulae, the definitions of the various groups are the same as those in claim 1.
12. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, characterized in that The Having a structure selected from the group consisting of: and / or the Having a structure selected from the group consisting of:
13. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein The R 2 Selected from H, D, CD3, halogen, hydroxyl, mercapto, cyano, C1-C3 alkyl, cyanomethyl, halogenated C1-C3 alkyl, C1-C3 alkoxy, vinyl, allyl.
14. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein The compound has a structure selected from the group consisting of: In another preferred embodiment, the compound of formula (I) has a structure selected from the following group: Or the compound of formula (Ia) has a structure selected from the following group: Or the compound of formula (II) has a structure selected from the following group: Or the compound of formula (II-a) has a structure selected from the following group:
15. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein The compound has a structure selected from the group consisting of:
16. The use of the compound according to claim 1, characterized in that Provided is a use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof for preparing a medicament for treating a disease associated with the activity or expression of a KRAS mutant; preferably, the disease is selected from the group consisting of a tumor, preferably a tumor selected from the group consisting of a sarcoma, a myxoma, a rhabdomyoma, a fibroma, a lipoma, a teratoma, a bronchial carcinoma, a lung cancer, a bronchial adenoma, a lymphoma, a chondroma hamartoma, a mesothelioma, an esophageal cancer, a gastric cancer, a pancreatic cancer, a small intestine cancer, a large intestine cancer, a cecal cancer, a genitourinary tract tumor, a kidney cancer, a bladder cancer, a urethral cancer, a prostate cancer, a testicular cancer, a liver cancer, a bile duct cancer, a hepatoblastoma, an angiosarcoma, a hepatocellular adenoma, a hemangioma, a gallbladder cancer, an ampullary cancer, a bile duct cancer, a bone cancer, a brain cancer, a uterine cancer, a vaginal cancer, a blood tumor, a skin cancer, and a breast cancer.
17. A pharmaceutical composition, comprising: (i) a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable carrier.
18. A pharmaceutically acceptable prodrug of the compound according to claim 1, characterized in that: The prodrug has a structure as shown below: Among them, R 12 Selected from the group consisting of hydrogen, methyl, methoxy, deuterated methyl, ethoxy, ethyl, isopropyl, cyclobutane, oxetanyl, cyclopentane, cyclohexyl, aryl, heteroaryl; R 13 Each is independently selected from the following group: methyl, trifluoromethyl, difluoromethyl, deuterated methyl, C2-C6 straight chain alkyl, isopropyl, tert-butyl, isobutyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C4-C6 oxacycloalkyl, C4-C6 oxacycloalkylmethyl, aryl, heteroaryl, benzyl; The remaining groups are as defined in claim 1.
Citation Information
Cited By
Specific PET (Polyethylene Terephthalate) molecular probe for targeting KRASG12D mutant as well as preparation method and application of specific PET molecular probe
CN120774939A
Ras inhibitors
WO2025240847A1
Methods of treating a ras protein-related disease or disorder
WO2025255438A1
Therapeutic compositions and methods for managing treatment-related effects
WO2025265060A1
Ras inhibitors
WO2026006747A1
